CN117645641A - 二苄基丁内酯糖苷类化合物、其制备方法和应用 - Google Patents
二苄基丁内酯糖苷类化合物、其制备方法和应用 Download PDFInfo
- Publication number
- CN117645641A CN117645641A CN202311139551.1A CN202311139551A CN117645641A CN 117645641 A CN117645641 A CN 117645641A CN 202311139551 A CN202311139551 A CN 202311139551A CN 117645641 A CN117645641 A CN 117645641A
- Authority
- CN
- China
- Prior art keywords
- monosaccharide
- compound
- group
- sugar
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Dibenzyl butyrolactone glycoside compound Chemical class 0.000 title claims abstract description 111
- 238000002360 preparation method Methods 0.000 title claims abstract description 87
- 229930182470 glycoside Natural products 0.000 title claims abstract description 55
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims abstract description 19
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000002159 abnormal effect Effects 0.000 claims abstract description 11
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 179
- 238000006243 chemical reaction Methods 0.000 claims description 61
- 150000002771 monosaccharide derivatives Chemical class 0.000 claims description 57
- 150000002772 monosaccharides Chemical class 0.000 claims description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 45
- 235000000346 sugar Nutrition 0.000 claims description 39
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 claims description 29
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 claims description 29
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 claims description 29
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 claims description 29
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 28
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 claims description 27
- 201000004681 Psoriasis Diseases 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 20
- 125000003147 glycosyl group Chemical group 0.000 claims description 20
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 10
- 230000004224 protection Effects 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000002453 idose derivatives Chemical class 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 150000008266 deoxy sugars Chemical class 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 3
- PNNNRSAQSRJVSB-ZXXMMSQZSA-N (2s,3r,4s,5r)-2,3,4,5-tetrahydroxyhexanal Chemical compound C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-ZXXMMSQZSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- 241000879217 Apocynum androsaemifolium Species 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 150000001299 aldehydes Chemical class 0.000 claims description 2
- 125000005257 alkyl acyl group Chemical group 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-DVKNGEFBSA-N alpha-D-quinovopyranose Chemical compound C[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-DVKNGEFBSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 2
- 125000005251 aryl acyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000011278 co-treatment Methods 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 230000000850 deacetylating effect Effects 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 150000002243 furanoses Chemical class 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 230000005484 gravity Effects 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 150000003214 pyranose derivatives Chemical class 0.000 claims description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 19
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract description 15
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract description 15
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000000707 stereoselective effect Effects 0.000 abstract description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 68
- 239000000543 intermediate Substances 0.000 description 53
- 239000007787 solid Substances 0.000 description 44
- 239000003795 chemical substances by application Substances 0.000 description 40
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 37
- 230000005764 inhibitory process Effects 0.000 description 28
- 239000002674 ointment Substances 0.000 description 25
- 230000028327 secretion Effects 0.000 description 25
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 23
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 21
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 19
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 230000002757 inflammatory effect Effects 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 17
- 239000007858 starting material Substances 0.000 description 17
- 238000001035 drying Methods 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 14
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- 102100024085 Alpha-aminoadipic semialdehyde dehydrogenase Human genes 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 101710135349 Venom phosphodiesterase Proteins 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 description 5
- 102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 150000002338 glycosides Chemical class 0.000 description 5
- 229960002751 imiquimod Drugs 0.000 description 5
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- ZITBJWXLODLDRH-UHFFFAOYSA-N (-)-wikstromol Chemical compound C1=C(O)C(OC)=CC(CC2C(C(=O)OC2)(O)CC=2C=C(OC)C(O)=CC=2)=C1 ZITBJWXLODLDRH-UHFFFAOYSA-N 0.000 description 3
- NEMMESQJOZVCAX-UHFFFAOYSA-N (4,5-diacetyloxyoxan-3-yl) acetate Chemical compound CC(=O)OC1COCC(OC(C)=O)C1OC(C)=O NEMMESQJOZVCAX-UHFFFAOYSA-N 0.000 description 3
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 3
- UCQAGVHISBIIKI-UHFFFAOYSA-N 3,3-dibenzyloxolan-2-one Chemical class O=C1OCCC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 UCQAGVHISBIIKI-UHFFFAOYSA-N 0.000 description 3
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 3
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 3
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- OHWCAVRRXKJCRB-ZFYZTMLRSA-N (2s,3r,4s,5s,6r)-2-methoxy-6-methyloxane-3,4,5-triol Chemical compound CO[C@H]1O[C@H](C)[C@@H](O)[C@H](O)[C@H]1O OHWCAVRRXKJCRB-ZFYZTMLRSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000019028 Epidermal thickening Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 2
- MAZXJZHWRBSRKM-ZFYZTMLRSA-N (2s,3s,4s,5r,6s)-2-(iodomethyl)-6-methoxyoxane-3,4,5-triol Chemical compound CO[C@H]1O[C@H](CI)[C@@H](O)[C@H](O)[C@H]1O MAZXJZHWRBSRKM-ZFYZTMLRSA-N 0.000 description 1
- KEJGAYKWRDILTF-JDDHQFAOSA-N (3ar,5s,6s,6ar)-5-[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-ol Chemical compound O1C(C)(C)OC[C@@H]1[C@@H]1[C@H](O)[C@H]2OC(C)(C)O[C@H]2O1 KEJGAYKWRDILTF-JDDHQFAOSA-N 0.000 description 1
- QXJDESBAUIILLG-UHFFFAOYSA-N 1,2,3,3,4,4,4-heptafluoro-1-iodobut-1-ene Chemical compound FC(I)=C(F)C(F)(F)C(F)(F)F QXJDESBAUIILLG-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- UWKQJZCTQGMHKD-UHFFFAOYSA-N 2,6-di-tert-butylpyridine Chemical compound CC(C)(C)C1=CC=CC(C(C)(C)C)=N1 UWKQJZCTQGMHKD-UHFFFAOYSA-N 0.000 description 1
- IEDVQOXHVRVPIX-UHFFFAOYSA-N 2-(oxolan-2-yl)acetic acid Chemical compound OC(=O)CC1CCCO1 IEDVQOXHVRVPIX-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- FWTJDTQXENOXPC-UHFFFAOYSA-N 3-benzyloxolan-2-one Chemical compound O=C1OCCC1CC1=CC=CC=C1 FWTJDTQXENOXPC-UHFFFAOYSA-N 0.000 description 1
- VEFDLKXOSOFUIN-UHFFFAOYSA-N 5-hydroxy-4-pentenoic acid d-lactone Chemical compound O=C1CCC=CO1 VEFDLKXOSOFUIN-UHFFFAOYSA-N 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QZQMGQQOGJIDKJ-IKOZNORXSA-N [(2s,3s,4r,5r)-4,5,6-triacetyloxy-2-methyloxan-3-yl] acetate Chemical compound C[C@@H]1OC(OC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O QZQMGQQOGJIDKJ-IKOZNORXSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- YFHNDHXQDJQEEE-UHFFFAOYSA-N acetic acid;hydrazine Chemical compound NN.CC(O)=O YFHNDHXQDJQEEE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940030999 antipsoriatics Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
- 229960001164 apremilast Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940064002 calcium hypophosphite Drugs 0.000 description 1
- 229910001382 calcium hypophosphite Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000048135 human PDE4D Human genes 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001660 hyperkinetic effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- CNALVHVMBXLLIY-IUCAKERBSA-N tert-butyl n-[(3s,5s)-5-methylpiperidin-3-yl]carbamate Chemical compound C[C@@H]1CNC[C@@H](NC(=O)OC(C)(C)C)C1 CNALVHVMBXLLIY-IUCAKERBSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000008135 α-glycosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D315/00—Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups C07D303/00 - C07D313/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
本发明提供了一种如式(I)所示的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐,其制备方法,包含其的药物组合物,以及其在制备预防、治疗或辅助治疗与磷酸二酯酶4(PDE4)活性水平或表达水平异常相关的疾病的药物中的用途。本发明的二苄基丁内酯糖苷类化合物对PDE4具有很强的抑制活性,并具有很强的抗炎活性,可以用于预防、治疗或辅助治疗与PDE4的活性和/或表达水平异常相关的疾病;此外,本发明提供的二苄基丁内酯糖苷类化合物的制备方法可以实现其立体选择性制备。
Description
交叉引用
本申请要求于2022年9月5日提交的、申请号为202211078981.2、发明名称为“二苄基丁内酯糖苷类化合物、其制备方法和应用”的中国专利申请的优先权,其全部内容通过引用并入本文。
技术领域
本发明涉及药物化学领域,具体涉及一种如式(I)所示的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐,其制备方法,包含其的药物组合物,以及其在制备磷酸二酯酶4抑制剂中的用途以及在制备用于预防、治疗或辅助治疗与磷酸二酯酶4活性水平或表达水平异常相关的疾病的药物中的用途。
背景技术
环核苷酸磷酸二酯酶(Cyclic nucleotide phosphodiesterases,PDEs)可以特异性催化水解细胞内第二信使环磷酸腺苷(cAMP)或环磷酸鸟苷(cGMP),调节cAMP或cGMP在细胞内的浓度,从而调控第二信使分子所介导的一系列生理病理过程,如细胞周期控制、细胞分化、炎症、心脏功能、平滑肌舒张与收缩、视觉信号传导、学习与记忆等。PDEs是环核苷酸信号传导通路中的重要调控蛋白,抑制其水解活性,可以提高细胞内cAMP或cGMP浓度,抑制多种炎症介质活性、抑制细胞粘附因子的上调和表达、诱导细胞凋亡以及诱导儿茶酚胺类物质和内源性激素的释放等。因此,PDEs是重要的药物作用靶标家族,PDEs抑制剂已经广泛应用于多种疾病病理机制研究及治疗(Maurice DH,et al.Nat.Rev.Drug Discov.2014,13:290-314;Menniti FS,et al.Nat.Rev.Drug Discov.2006,5(8),660-670)。
PDE4特异性水解细胞内第二信使分子cAMP,是PDE超家族中11个亚家族中的一员,包含PDE4A/B/C/D四种亚型,在体内分布广泛,主要表达于多种免疫相关细胞如中性粒细胞、嗜酸性粒细胞和单核细胞等。因此,PDE4成为免疫及炎症相关疾病中主要的抗炎药物研究的重要靶点。PDE4涉及的疾病种类繁多,其中与PDE4在炎症进程中的作用相关的有慢性阻塞性肺疾病、哮喘、银屑病、过敏性鼻炎、特发性肺纤维化和风湿性关节炎等疾病。涉及神经系统的疾病包括阿尔兹海默症、帕金森氏症、抑郁症和精神分裂症等(Menniti FS,etal.Nat.Rev.Drug Discov.2006,5:660-670;BurginAB,et al.Nat.Biotechnol.2010,28:63-70;Garcia OstaA,et al.ACS Chem.Neurosci.2012,3:832-844)。由于PDE4涉及多种重要疾病且已有部分PDE4抑制剂用于临床治疗,设计和发现PDE4的新型抑制剂是新药研发领域的一大热点。
银屑病是一种常见的慢性复发性炎症性皮肤病,典型临床表现为边界清楚的红斑、皮疹、斑块、鳞屑,该病发病机制复杂,病因未明。肿瘤坏死因子α(TNF-α)在银屑病中高度表达,针对TNF-α的阻断治疗在临床上效果显著。靶向抑制PDE4水解活性可以通过增加细胞内cAMP浓度下调TNF-α等促炎因子的表达,缓解银屑病症状。目前银屑病治疗多以局部治疗为主,类固醇类激素如丁酸氢化可的松、糠酸莫米松等在治疗银屑病中应用广泛,但长期使用副作用大,影响其广泛应用;他克莫司、卡波三醇等由于其昂贵的价格也限制了其在临床上的应用。虽然目前为止用于治疗银屑病的PDE4抑制剂逐步上市,如Crisaborole和Apremilast,但仍在巨大缺口,迫切需要研发新的副作用更少、经济成本更低以及疗效更好药物。
牛蒡子苷(Arctiin)及其苷元牛蒡子苷元(Arctigenin)来源于牛蒡,属于二苄基丁内酯类化合物,具有多种药理活性,包括免疫调节、抗糖尿病、抗肿瘤、神经保护等作用。其结构式如下所示:
许多研究表明,牛蒡子苷和牛蒡子苷元可以通过抑制NO和PGE2释放、抑制COX2活性、抑制活性氧生成等多种途径抑制TNF-α、IL-1β、IL-6等炎症因子释放,发挥抗炎效果(Gao,et al.Acta Pharmacol.Sin.2018,39:787-801)。近年来研究表明,牛蒡子苷元可以通过抑制PDE4D,升高体内cAMP水平,发挥显著的抗炎与抗银屑病效果(Li,etal.J.Adv.Res.2021,33:241-251),但其也存在溶解性差、代谢迅速等问题,阻碍了其作为药物开发的潜力,对牛蒡子苷元进行进一步结构改造有望获得具有更好抗炎活性、更好成药性的候选化合物。
在药物化学领域,糖类药物的研究越来越受到重视。糖类化合物结构的复杂与多样性赋予了母体药物多样化的理化性质与药理活性。天然产物的糖基化修饰可以通过增加溶解性、调节血浆半衰期、提高结合特异性等方式改变母体药物的药理活性(蔡孟深,李中军.糖化学[M].化学工业出版社,2007,315-324)。然而,牛蒡子苷元天然来源的糖苷——牛蒡子苷对PDE4D的抑制活性偏弱,细胞水平的抗炎活性微弱。
目前,尚未有对此类二苄基丁内酯类化合物进行的多种糖基化修饰报道,不同糖基化修饰对该类化合物的药理活性的影响仍有待探究。
此外,区域及立体选择性地构筑糖苷键在糖类化合物合成领域一直是很大的挑战(Shivatare,et al.J.Org.Chem.2020,85,15780-15800)。目前也尚未报道以二苄基丁内酯类化合物和糖基供体为原料选择性构筑糖苷键的方法,由此带来立体异构体拆分困难的问题,极大限制了此类糖苷的大规模制备。
发明内容
本发明的目的在于提供一种如式(I)所示的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐,其制备方法,包含其的药物组合物,以及其在制备磷酸二酯酶4抑制剂中的用途以及在制备用于预防、治疗或辅助治疗与磷酸二酯酶4活性水平或表达水平异常相关的疾病的药物中的用途。本发明的如式(I)所示的二苄基丁内酯糖苷类化合物对于PDE4D具有很强的抑制活性,其抗炎效果也显著优于母体化合物牛蒡子苷元的天然产物来源——牛蒡子苷(Arctiin),在与磷酸二酯酶4活性水平或表达水平异常相关的疾病的临床治疗中具有广阔的应用前景。
本发明的上述目的通过以下技术方案来实现:
第一方面,本发明提供了一种如式(I)所示的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐:
所述式(I)中,R选自由以下组成的组:单糖、单糖衍生物、由单糖单元通过糖苷键连接的双糖、由三至五个单糖单元通过糖苷键连接的寡糖;其中,所述单糖不包含D-β-葡萄糖,但所述单糖衍生物包含D-β-葡萄糖衍生物,并且,其中,所述R通过α或β型O-糖苷键与二苄基丁内酯类化合物主体相连。
在优选的实施方案中,所述单糖选自:呋喃糖和吡喃糖;
优选地,所述单糖为D型或L型。
在优选的实施方案中,所述单糖衍生物选自由以下组成的组:氧化糖、卤代糖、不饱和糖、去氧糖、氨基去氧糖、脱水糖、硫酸化糖、磷酸化糖、歧链糖、糖基烷基化衍生物和糖基酯化衍生物;
进一步优选地,所述氧化糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被氧化为醛或酸所得的单糖衍生物;
进一步优选地,所述卤代糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被卤素取代所得的单糖衍生物,所述卤素任意地选自氟、氯、溴或碘;
进一步优选地,所述不饱和糖选自单糖或单糖衍生物上任意相邻两个羟基变为不饱和双键所得的单糖衍生物;
进一步优选地,所述去氧糖或氨基去氧糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被替换为甲基所得的单糖衍生物;
进一步优选地,所述脱水糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被替换为氢原子所得的单糖衍生物;
进一步优选地,所述硫酸化糖或磷酸化糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被硫酸基或磷酸基修饰所得的单糖衍生物;
进一步优选地,所述歧链糖选自单糖或单糖衍生物上任意1,2,3,4或5个非端基碳原子上各自独立地有一个碳取代基所得的单糖衍生物,所述碳取代基可以置换为一个氢原子或一个羟基;
进一步优选地,所述糖基烷基化衍生物选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被直链或支链的烷基修饰所得的单糖衍生物,所述烷基为C1-C10烷基或亚烷基、C1-C8卤代烷基、C3-C10环烷基、3-8元杂环烷基、C6-C10芳基、3-8元芳杂环基、3-8元杂环烷基C1-C8亚烷基、3-8元环烷基C1-C8亚烷基或C6-C10芳基C1-C8亚烷基;
进一步优选地,所述糖基酯化衍生物选自由单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地与直链或支链的酰基组成酯键所得的单糖衍生物,所述酰基各自独立地为C1~C10烷基酰基、C1-C8卤代烷基酰基、C3-C10环烷基酰基、3-8元杂环烷基酰基、C6-C10芳基酰基、3-8元芳杂环基酰基、3-8元杂环烷基C1-C8亚烷基酰基、3-8元环烷基C1-C8亚烷基酰基或C6-C10芳基C1-C8亚烷基酰基,优选为乙酰基、丙酰基、异丁酰基、苯甲酰基。
在进一步优选的实施方案中,所述单糖衍生物选自由以下组成的组:卤代糖、不饱和糖、糖基烷基化衍生物和糖基酯化衍生物;
优选地,所述卤代糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被氟、氯、溴、碘原子取代;
优选地,所述不饱和糖选自单糖或单糖衍生物上任意相邻两个羟基变为不饱和双键所得的单糖衍生物;
优选地,所述糖基烷基化衍生物选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被甲基、乙基、环丙基、苄基或对甲氧基苄基所取代,或任意两个羟基通过亚甲基、亚乙基、异亚丙基、苯亚甲基组成环状缩醛或缩酮所得的单糖衍生物;
优选地,所述糖基酯化衍生物选自由单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地与乙酰基、丙酰基、异丁酰基或苯甲酰基组成酯键所得的单糖衍生物。
在进一步优选的实施方案中,式(I)中的所述R选自如下糖基或糖基衍生物:
柔红霉糖、阿洛糖、阿卓糖、古洛糖、半乳糖、氨基半乳糖、氨基葡萄糖、甘露糖、艾杜糖、塔洛糖、来苏糖、阿拉伯糖、核糖、木糖、岩藻糖、鼠李糖、异鼠李糖、橄榄霉糖、毛地黄毒糖、加拿大麻糖、奎诺糖、艾杜糖、6-脱氧艾杜糖、N-乙酰葡萄糖胺、N-乙酰半乳糖胺、果糖,或前述任意一项的衍生物,或D-β-葡萄糖衍生物。
在优选的具体实施方案中,如式(I)所示的二苄基丁内酯糖苷类化合物选自由如下化合物组成的组:
进一步优选地,所述化合物选自以下:
/>
/>
更进一步优选地,所述化合物选自以下:
/>
更进一步优选地,所述化合物为:
/>
/>
第二方面,本发明提供了如上述第一方面所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐的制备方法,所述制备方法包括以下步骤:
(1)牛蒡子苷元与乙酰基保护的糖,在氮气保护下,在催化剂作用下,经取代反应,形成乙酰基保护的牛蒡子糖苷化合物;
(2)在碳酸钾或甲醇钠存在下,使步骤(1)所得乙酰基保护的牛蒡子糖苷化合物脱去乙酰基保护,得到所述二苄基丁内酯糖苷类化合物。
在优选的实施方案中,步骤(1)中,所述催化剂选自:三氟甲磺酸三甲基硅酯、三氟甲磺酸、三氟化硼乙醚、三氯化铁,优选为三氟化硼乙醚;
在优选的实施方案中,步骤(1)中,所述取代反应在溶剂中进行,所用溶剂选自:二氯甲烷、1,2-二氯乙烷、1,4-二氧六环,优选为二氯甲烷;
在优选的实施方案中,步骤(1)中,所述取代反应在-60℃~0℃,优选-50℃~0℃的温度下进行;
在优选的实施方案中,步骤(1)中,所述牛蒡子苷元与乙酰基保护的糖的摩尔比为0.05~3,优选为0.1~2;催化剂与牛蒡子苷元的摩尔比为0.008~1.2,优选为0.01~1。
在优选的实施方案中,步骤(2)中,所用溶剂选自:二氯甲烷、丙酮、乙酸乙酯、甲醇、乙醇,优选为甲醇;
在优选的实施方案中,步骤(2)中,反应温度为20~30℃,优选为室温。
在一些优选的具体实施方案中,步骤(1)中,所述乙酰基保护的糖具有如下结构式:
所述制备方法按如下工艺路线:
其中,Ra选自:H、-CH2OAc、-CH3;
当Ra为H时,Rh也为H;当Ra为-CH2OAc时,Rh为-CH2OH;当Ra为-CH3时,Rh为-CH3。
第三方面,本发明提供了一种药物组合物,其包括如上述第一方面所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐,以及药学上可接受的辅料。
在优选的实施方案中,所述二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐与药学上可接受的辅料的比重在0.001至100的范围内,优选在0.001至10范围内。
第四方面,本发明提供了如上述第一方面所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐在制备磷酸二酯酶4抑制剂、优选磷酸二酯酶4D抑制剂中的用途。
第五方面,本发明提供了如上述第一方面所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐或者如上述第三方面所述的药物组合物在制备用于预防、治疗或辅助治疗与磷酸二酯酶4(PDE4)活性水平和/或表达水平异常相关的疾病的药物中的用途。
优选地,所述PDE4为PDE4A、4B、4C或4D,优选PDE4D;
优选地,所述疾病为与PDE4A、4B、4C或4D(特别是与PDE4D)活性水平和/或表达水平异常相关的免疫和/或炎症性疾病;
进一步优选地,所述疾病选自由以下组成的组:银屑病、银屑病关节炎、特应性皮炎、白塞氏病、脂溢性皮炎、过敏性皮炎、慢性阻塞性肺病、哮喘、过敏性鼻炎、强直性脊柱炎、系统性红斑狼疮、风湿性关节炎、类风湿性关节炎、炎症性肠病、恶性胶质瘤、肺纤维化、肌萎缩性侧索硬化症、多发性硬化症、阿尔兹海默症、亨廷顿舞蹈症、帕金森氏症、多动症、抑郁症和精神分裂症。
有益效果
本发明的发明人经过长期而深入的研究,制备得到了一类能够抑制磷酸二酯酶(PDE4)的式I化合物;本发明的如式(I)所示的特定糖基修饰的二苄基丁内酯类化合物对四型磷酸二酯酶(PDE4)、特别是PDE4D具有很强的抑制活性,并具有很强的抗炎活性,可以用于预防、治疗或辅助治疗与磷酸二酯酶4的活性和/或表达水平异常相关的疾病,例如银屑病、银屑病关节炎、特应性皮炎、白塞氏病、脂溢性皮炎、过敏性皮炎、慢性阻塞性肺病、哮喘、过敏性鼻炎、强直性脊柱炎、系统性红斑狼疮、风湿性关节炎、类风湿性关节炎、炎症性肠病、恶性胶质瘤、肺纤维化、肌萎缩性侧索硬化症、多发性硬化症、阿尔兹海默症、亨廷顿舞蹈症、帕金森氏症、多动症、抑郁症和精神分裂症等疾病,尤其是与PDE4相关的免疫和炎症性疾病如银屑病和关节炎等,其效果显著优于母体化合物牛蒡子苷元的天然产物来源糖苷——牛蒡子苷(Arctiin)。
此外,本发明所提供的如式(I)所示二苄基丁内酯类化合物的制备方法,通过改进催化剂用量和反应温度并基于热力学控制原理等,实现了二苄基丁内酯糖苷类化合物的大批量立体选择性制备,这对于此类化合物的临床药用具有非常重要的现实意义与良好的应用前景。
附图说明
一个或多个实施例通过与之对应的附图中的图片进行示例性说明,这些示例性说明并不构成对实施例的限定。在这里,专用的词“示例性”意为“用作例子、实施例或说明性”。在这里,作为“示例性”所说明的任何实施例不必解释为优于或好于其它实施例。
图1为实施例8中记载的化合物AG09对PDE4D催化结构域的半抑制浓度曲线;
图2为实施例9中记载的化合物AG09对人PBMC细胞中炎症因子TNF-α分泌的半抑制浓度曲线;
图3为实施例11中记载的AG09软膏剂治疗银屑病小鼠的皮肤损伤的外观变化;从左至右分别为正常对照组,模型对照组,AG09软膏剂2%治疗组、AG09软膏剂5%治疗组;
图4为实施例11中记载的AG09软膏剂治疗银屑病小鼠的皮肤损伤的病理组织照片变化;从左至右分别为正常对照组,模型对照组,AG09软膏剂2%治疗组、AG09软膏剂5%治疗组;
图5为实施例11中记载的AG09软膏剂治疗银屑病小鼠的皮肤厚度变化;从左至右分别为正常对照组,模型对照组,AG09软膏剂2%治疗组、AG09软膏剂5%治疗组。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
另外,为了更好的说明本发明,在下文的具体实施方式中给出了众多的具体细节。本领域技术人员应当理解,没有某些具体细节,本发明同样可以实施。在一些实施例中,对于本领域技术人员熟知的原料、方法等未作详细描述,以便于凸显本发明的主旨。
除非另有其它明确表示,否则在整个说明书和权利要求书中,术语“包括”或其变换如“包含”或“包括有”等等将被理解为包括所陈述的组成部分,而并未排除其它组成部分。
此外,需要说明的是,本发明所有数值指定均可理解为前面有术语“约”。
以下实施例中,未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件;除非另外说明,否则百分比和份数按重量计算。
以下实施例中,所用化合物可以从市售获得或可通过以下使用市售的原料和试剂的常规方法合成。
以下实施例中,1H NMR谱与13C NMR采用Bruker-500MHz型核磁共振仪测定,MS谱在Finnigan LTQ线性离子阱质谱仪上测定,反应用TLC跟踪,HPLC制备和纯度测定(乙腈、水为流动相,添加1‰三氟乙酸)在大连依利特P3140A/P型仪器上进行,所有反应未作特别说明均在空气氛围下进行。
此外,实施例中使用了以下缩略语:
PE 石油醚
EA 乙酸乙酯
TEA 三乙胺
DCM 二氯甲烷
TMSOTf 三氟甲磺酸三甲基硅酯。
实施例1
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合物AG02:
中间体2R,3R,4S,5R,6S-2-乙酰氧基甲基-6-(3R,4R)-4-(3,4-二甲氧基苄基)-2- 氧代四氢呋喃-3-基)甲基-2-甲氧基苯氧基四氢-2H-吡喃-3,4,5-三基三乙酸酯(化合物1- 1)的合成:
将牛蒡子苷元(100mg,0.268mmol)和2,3,4,6-四-O-乙酰基-β-D-吡喃半乳糖酰基-2,2,2-三氯代亚氨乙酸酯(132mg,0.268mmol)加入溶于无水二氯甲烷(3mL)中,N2保护,0℃下缓慢滴加TMSOTf(6mg,0.027mmol),缓慢升至室温后反应12h。反应完成后,旋干有机相,快速柱层析分离(PE:EA=1:1)得无色油状物,即为中间体化合物1-1,其产量为130mg,收率为69.1%。
化合物3R,4R-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(2S,3R,4S,5S,6R)-3,4, 5-三羟基-6-羟甲基四氢-2H-吡喃-2-基)苄基)二氢呋喃-2(3H)-酮(AG02)的制备:
将化合物1-1(100mg,0.142mmol)溶于甲醇(2mL)中,加入无水碳酸钾(49mg,0.355mmol),室温反应3h。反应完成后,旋干有机相,柱层析分离(DCM:MeOH=10:1),得白色固体,即为化合物AG02,其产量为55mg,收率为72.4%。1H NMR(500MHz,Chloroform-d)δ6.97(d,J=8.1Hz,1H),6.75(dd,J=8.3,2.8Hz,1H),6.65–6.58(m,2H),6.55(dd,J=8.1,2.1Hz,1H),6.48(d,J=2.1Hz,1H),4.72(d,J=7.6Hz,1H,1-H),4.18–4.07(m,2H),4.01–3.93(m,1H),3.89–3.81(m,6H),3.79(s,3H),3.74–3.71(m,1H),3.69(s,3H),3.61–3.54(m,1H),2.88–2.84(m,2H),2.68–2.62(m,1H),2.59–2.51(m,2H),2.51–2.44(m,1H).13C NMR(126MHz,CDCl3)δ178.16,149.03,148.53,147.37,144.52,132.91,129.85,121.40,120.22,117.33,112.64,111.46,110.96,102.26(1-C),74.17,72.68,70.74,70.57,68.32,61.00,55.44,55.42,55.37,45.94,40.63,37.58,33.98.HRMS:m/z for C27H34NaO11[M+Na]+calculated:557.1993,found:557.1987.
实施例2
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合物AG03:
中间体2R,3R,4S,5S,6R-2-乙酰氧基甲基-6-(4-(3R,4R)-4-(3,4-二甲氧基苄
基)-2-氧代四氢呋喃-3-基)甲基)-2-甲氧基苯氧基-2H-吡喃-3,4,5-三基三乙酸酯(化合
物2-1)的合成:
将牛蒡子苷元(200mg,0.537mmol)和1,2,3,4,6-O-五乙酰基-α-甘露糖(105mg,0.269mmol)溶于无水1,2-二氯乙烷(5mL)中,N2保护,0℃下缓慢滴加三氟甲磺酸(3mg,0.02mmol),缓慢升至室温后反应12h。反应完成后,旋干有机相,快速柱层析分离(PE:EA=1:1)得无色油状物,即为中间体化合物2-1,其产量为135mg,收率为71.8%。
化合物3R,4R-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(2R,3S,4S,5S,6R)-3,4,
5-三羟基-6-羟甲基四氢-2H-吡喃-2-基)氧基)苄基)二氢呋喃-2(3H)-酮(AG03)的制备:
参照AG02的制备方法,得白色固体,即为化合物AG03,其产量为45mg,收率为74.3%。1H NMR(500MHz,Chloroform-d)δ6.96(d,J=8.0Hz,1H),6.75(d,J=8.1Hz,1H),6.67–6.62(m,1H),6.59(d,J=8.1Hz,1H),6.55(dd,J=8.1,1.9Hz,1H),6.49(d,J=1.9Hz,1H),5.46(s,1H),4.24(s,1H,1-H),4.15–4.10(m,2H),4.00–3.93(m,2H),3.87–3.82(m,4H),3.81–3.76(m,4H),3.74–3.66(m,4H),2.88(d,J=5.7Hz,2H),2.64(dd,J=13.6,6.1Hz,1H),2.56(dt,J=8.2,5.4Hz,2H),2.47(q,J=7.5Hz,1H).13C NMR(126MHz,CDCl3)δ178.63,150.29,149.04,147.89,144.16,133.25,130.38,121.67,120.68,118.12,113.43,111.97,111.46,99.78(1-C),73.14,71.44,71.22,70.90,66.12,60.88,55.92,55.91,55.86,46.47,41.11,38.09,34.46.HRMS:m/z for C27H34NaO11[M+Na]+calculated:557.1993,found:557.1990.
实施例3
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合物AG04和AG05:
中间体2R,3R,4S,5R-2-乙酰氧基甲基-5-(4-(3R,4R)-4-(3,4-二甲氧基苄基)-2-
氧代四氢呋喃-3-基)甲基-2-甲氧基苯氧基四氢呋喃-3,4-二基二乙酸酯(化合物3-1)和中
间体2R,3R,4S,5S-2-乙酰氧基甲基-5-(4-(3S,4S)-4-(3,4-二甲氧基苄基)-2-氧代四氢呋
喃-3-基甲基)-2-甲氧基苯氧基四氢呋喃-3,4-二基二乙酸酯(化合物4-1)的制备:
将牛蒡子苷元(1.0g,2.69mmol)和四乙酰阿拉伯呋喃糖(570mg,1.79mmol)溶于无水DCM(20mL)中,N2保护,0℃下缓慢滴加1mol/L三氟化硼乙醚溶液(3.58mL,3.58mmol),升至室温后反应12h。反应完成后,旋干有机相,快速柱层析分离(PE:EA=1:1),分别得到两种立体异构体化合物:化合物3-1和化合物4-1。化合物3-1为白色固体,产量为350mg,收率为30.1%;化合物4-1为白色固体,产量为430mg,收率为38.1%。
化合物3R,4R-3-(4-(2R,3S,4S,5R)-3,4-二羟基-5-羟甲基四氢呋喃-2-基)氧基-
3-甲氧基苄基)-4-(3,4-二甲氧基苄基)二氢呋喃-2(3H)-酮(AG04)的制备:
参照AG02的制备方法,得白色固体,即为化合物AG04,其产量为57mg,收率为71.6%。1H NMR(500MHz,Chloroform-d)δ6.98(d,J=8.0Hz,1H),6.75(d,J=8.1Hz,1H),6.71–6.66(m,2H),6.54(dd,J=8.1,2.0Hz,1H),6.50(d,J=2.2Hz,1H),5.72(s,1H,1-H),4.32(s,1H),4.29–4.24(m,1H),4.16(dd,J=9.1,7.1Hz,1H),4.12(s,1H),3.93–3.83(m,6H),3.82(s,3H),3.78(s,3H),2.98–2.91(m,2H),2.65(dd,J=13.3,6.1Hz,1H),2.62–2.55(m,2H),2.54–2.48(m,1H).13C NMR(126MHz,CDCl3)δ178.07,150.54,148.56,147.43,142.06,132.90,129.83,121.25,120.11,117.51,112.40,111.45,110.91,106.75(1-C),87.92,78.43,77.71,70.78,61.51,55.42,55.41,55.16,46.03,40.58,37.67,34.09.HRMS:m/z for C26H32NaO10[M+Na]+calculated:527.1888,found:557.1885.
化合物3R,4R-3-(4-(2S,3S,4S,5R)-3,4-二羟基-5-羟甲基四氢呋喃-2-基)氧基-
3-甲氧基苄基)-4-(3,4-二甲氧基苄基)二氢呋喃-2(3H)-酮(AG05)的制备:
参照AG02的制备方法,得白色固体,即为化合物AG05,其产量为66mg,收率为63.5%。1H NMR(500MHz,Chloroform-d)δ7.05(d,J=8.1Hz,1H),6.76(dd,J=8.2,2.3Hz,1H),6.71(d,J=2.0Hz,1H),6.63(dd,J=8.2,1.9Hz,1H),6.56(dd,J=8.1,2.0Hz,1H),6.49(t,J=2.5Hz,1H),4.75(d,J=6.5Hz,1H,1-H),4.15(dd,J=9.1,7.4Hz,1H),4.10–4.01(m,1H),4.00–3.95(m,2H),3.91–3.84(m,4H),3.82(s,3H),3.81–3.74(m,4H),3.60(dd,J=12.4,1.8Hz,1H),2.93(d,J=5.8Hz,2H),2.65(dd,J=13.8,6.5Hz,1H),2.61–2.53(m,2H),2.52–2.43(m,1H).13C NMR(126MHz,CDCl3)δ178.07,149.81,148.58,147.44,143.92,133.51,129.83,121.31,120.13,118.74,112.57,111.40,110.88,102.19(1-C),72.15,70.76,70.10,66.75,64.77,55.43,55.42,55.41,46.03,40.52,37.70,34.03.HRMS:m/z for C26H32NaO10[M+Na]+calculated:527.1888,found:557.1876.
实施例4
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合物AG06和AG07:
中间体2-乙酰氧基甲基-5-(3R,4R)-4-(3,4-二甲氧基苄基)-2-氧代四氢呋喃-3-
基甲基)-2-甲氧基苯氧基-3-二氢呋喃-3-二乙酸酯(化合物5-1)和中间体2-乙酰氧基甲
基-5-(3S,4S)-4-(3,4-二甲氧基苄基)-2-氧代四氢呋喃-3-基甲基)-2-甲氧基苯氧基-3,
4-二氢呋喃-3,4-二基二乙酸酯(化合物6-1)的制备:
参照化合物3-1和化合物4-1的制备方法,以牛蒡子苷元和3,4,5-三乙酰氧基氧杂环戊环-2-基乙酸甲酯为起始原料,得化合物5-1,其为白色固体,产量为370mg,收率为32.7%;得化合物6-1,其为无色固体,产量为470mg,收率为41.6%。
化合物3R,4R-3-(4-(2R,3S,4R,5S)-3,4-二羟基-5-羟甲基四氢呋喃-2-基)氧基-
3-甲氧基苄基)-4-(3,4-二甲氧基苄基)二氢呋喃-2(3H)-酮(AG06)的制备:
参照AG02的制备方法,得无色固体,即为化合物AG06,其产量为72mg,收率为77.3%。1H NMR(500MHz,Chloroform-d)δ6.94(d,J=8.1Hz,1H),6.77–6.73(m,1H),6.69(d,J=2.0Hz,1H),6.64–6.60(m,1H),6.57–6.53(m,1H),6.50–6.46(m,1H),5.53(s,1H,1-H),4.68(t,J=5.5Hz,1H),4.39(d,J=4.9Hz,1H),4.21–4.13(m,2H),3.90(dd,J=9.1,7.6Hz,1H),3.87–3.83(m,4H),3.82(s,3H),3.79(s,3H),3.71(dd,J=12.4,3.0Hz,1H),2.96–2.90(m,2H),2.67–2.61(m,1H),2.59–2.53(m,2H),2.52–2.45(m,1H).13C NMR(126MHz,CDCl3)δ178.12,150.11,148.52,147.40,144.12,133.05,129.84,121.49,120.15,118.25,112.78,111.37,110.86,107.88(1-C),84.86,75.50,70.84,69.74,61.39,55.42,55.37,55.22,46.04,40.52,37.78,34.04.HRMS:m/z for C26H32NaO10[M+Na]+calculated:527.1888,found:557.1879.
化合物3R,4R-3-(4-(2S,3S,4R,5S)-3,4-二羟基-5-羟甲基四氢呋喃-2-基)氧基-
3-甲氧基苄基)-4-(3,4-二甲氧基苄基)二氢呋喃-2(3H)-酮(AG07)的制备:
参照AG02的制备方法,得无色固体,即为化合物AG07,其产量为68mg,收率为68.9%。1H NMR(500MHz,Chloroform-d)δ6.82(d,J=1.9Hz,1H),6.74(d,J=8.1Hz,1H),6.64(d,J=2.0Hz,1H),6.63–6.55(m,2H),6.51(dd,J=8.8,2.1Hz,1H),5.34(t,J=4.5Hz,1H,1-H),4.49(t,J=4.0Hz,1H),4.38(dd,J=7.9,4.6Hz,1H),4.15(dt,J=9.0,6.5Hz,1H),4.06(dt,J=7.8,3.7Hz,1H),3.97(dd,J=11.9,3.1Hz,1H),3.90(dt,J=12.8,4.6Hz,1H),3.85(d,J=5.2Hz,7H),3.82(d,J=2.3Hz,3H),2.97–2.90(m,2H),2.70(dd,J=13.4,6.3Hz,1H),2.57(dq,J=8.5,5.1Hz,2H),2.50(q,J=7.4Hz,2H).13C NMR(126MHz,CDCl3)δ178.26,148.53,147.50,145.87,140.46,130.01,128.77,122.13,120.38,119.86,112.02,111.02,110.65,81.93,78.72,72.67,72.06,70.88,62.05,55.73,55.61,55.46,46.19,40.52,37.71,34.18.HRMS:m/z for C26H32NaO10[M+Na]+calculated:527.1888,found:557.1885.
实施例5
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合物AG08和AG09:
中间体(2R,3R,4S,5R)-2-(4-(((3R,4R)-4-(3,4-甲氧基苄基)-2-氧代四氢呋喃-
3-基)甲基)-2-甲氧基苯氧基)四氢-2H-吡喃-3,4,5-三乙酸三酯(化合物7-1)和化合物
(2S,3R,4S,5R)-2-(4-(((3R,4R)-4-(3,4-甲氧基苄基)-2-氧代四氢呋喃-3-基)甲基)-2-
甲氧基苯氧基)四氢-2H-吡喃-3,4,5-三乙酸三酯(化合物8-1)的制备:
参照化合物3-1和化合物4-1的制备方法,以牛蒡子苷元和1,2,3,4-四-O-乙酰-β-D-吡喃木糖为起始原料,得化合物7-1,其为白色固体,产量为435mg,收率为33.5%;得化合物8-1,其为无色固体,产量为585mg,收率为45.8%。
化合物3R,4R-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(2R,3R,4S,5R)-3,4,5-三
羟基四氢-2H-吡喃-2-基)氧基苄基)二氢呋喃-2(3H)-酮(AG08)的制备:
参照AG02的制备方法,得无色固体,即为化合物AG08,其产量为230mg,收率为73.9%。1H NMR(500MHz,Chloroform-d)δ7.04(d,J=8.0Hz,1H),6.76(dd,J=8.3,2.1Hz,1H),6.68(d,J=1.9Hz,1H),6.63(dd,J=8.2,1.9Hz,1H),6.56(dd,J=8.1,2.0Hz,1H),6.47(d,J=2.0Hz,1H),5.24(d,J=3.7Hz,1H,1-H),4.16(dd,J=9.1,7.4Hz,1H),3.94–3.87(m,1H),3.85(s,3H),3.82–3.79(m,6H),3.79–3.77(m,4H),3.60(dd,J=9.3,3.7Hz,1H),2.93(dd,J=6.1,3.0Hz,2H),2.65–2.62(m,1H),2.59–2.55(m,2H),2.49–2.45(m,1H).13C NMR(126MHz,CDCl3)δ178.07,149.96,148.57,147.41,144.48,133.47,129.85,121.41,120.19,118.84,112.39,111.37,110.87,100.16(1-C),74.67,71.92,70.79,69.19,62.07,55.44,55.40,55.37,46.02,40.50,37.73,34.07.HRMS:m/z for C26H32NaO10[M+Na]+calculated:527.1888,found:557.1875.
化合物3R,4R-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(2S,3R,4S,5R)-3,4,5-三
羟基四氢-2H-吡喃-2-基)氧基)苄基二氢呋喃-2(3H)-酮(AG09)的制备:
参照AG02的制备方法,得无色固体,即为化合物AG09,其产量为320mg,收率为70.7%。1H NMR(400MHz,Chloroform-d)δ7.03(d,J=8.1Hz,1H),6.79–6.69(m,2H),6.64(dd,J=8.1,2.0Hz,1H),6.55(dd,J=8.1,2.0Hz,1H),6.49(d,J=2.0Hz,1H),4.91(d,J=5.3Hz,1H,1-H),4.17(dd,J=9.1,7.3Hz,1H),4.10(dd,J=11.9,4.3Hz,1H),3.93–3.84(m,5H),3.83–3.78(m,6H),3.74–3.65(m,2H),3.40(dd,J=12.0,7.9Hz,1H),2.99–2.90(m,2H),2.65(dd,J=13.7,6.7Hz,1H),2.61–2.54(m,2H),2.50–2.42(m,1H).13C NMR(101MHz,CDCl3)δ178.56,150.22,149.08,147.94,144.26,133.93,130.31,121.80,120.63,118.83,113.05,111.92,111.43,102.54(1-C),74.53,72.11,71.28,69.41,64.57,55.93,55.90,55.89,46.50,41.03,38.20,34.54.HRMS:m/z for C26H32NaO10[M+Na]+calculated:527.1888,found:557.1888.
实施例6
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合物AG10:
中间体2S,3S,4R,5R,6S-2-(3R,4R)-4-(3,4-二甲氧基苄基)-2-氧代四氢呋喃-3-
基)甲基-2-甲氧基苯氧基-6-甲基四氢-2H-吡喃-3,4,5-三基三乙酸酯(化合物9-1)的制
备:
参照化合物3-1和化合物4-1的制备方法,以牛蒡子苷元和1,2,3,4-四-O-乙酰基-α-L-岩藻吡喃糖苷为起始原料,得白色固体,即为化合物9-1,其产量为365mg,收率为67.7%。
化合物3R,4R-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(2S,3S,4R,5S,6S)-3,4,5-
三羟基-6-甲基四氢-2H-吡喃-2-氧基)苄基)二氢呋喃-2(3H)-酮(AG10)的制备:
参照AG02的制备方法,得白色固体,即为化合物AG10,其收率为73.6%。1H NMR(500MHz,Chloroform-d)δ7.07(d,J=8.0Hz,1H),6.76(d,J=8.0Hz,1H),6.72(d,J=1.9Hz,1H),6.67–6.60(m,1H),6.57(dd,J=8.1,2.0Hz,1H),6.50(d,J=2.0Hz,1H),5.25(d,J=3.7Hz,1H,1-H),4.27(q,J=6.7Hz,1H),4.18–4.12(m,1H),4.02(dd,J=9.6,3.1Hz,1H),3.94–3.88(m,3H),3.86(s,3H),3.82(s,3H),3.80(s,3H),2.99–2.90(m,2H),2.67–2.64(m,1H),2.61–2.55(m,2H),2.48(q,J=7.7Hz,1H),1.34(d,J=6.6Hz,3H).13C NMR(126MHz,CDCl3)δ178.05,150.11,148.60,147.47,144.94,133.41,129.83,121.46,120.13,119.06,112.33,111.39,110.93,100.83(1-C),71.00(2C),70.74,68.90,66.74,55.45,55.39,55.28,46.03,40.50,37.66,34.00,15.74.ESI-MS:[M+Na]+:541.4.
实施例7
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合AG31:
化合物(2S,3R,4S,5R)-2-(4-(((3R,4R)-4-(3,4-二甲氧基苄基)-2-氧代四氢呋
喃-3-基)甲基)-2-甲氧基苯氧基)四氢-2H-吡喃-3,4,5-三基三乙酸酯(AG31)的制备
将牛蒡子苷元(2.5g,6.71mmol)和1,2,3,4-四-O-乙酰-β-D-吡喃木糖(1.42g,4.48mmol)和烘干的分子筛溶于无水DCM(50mL)中,N2保护下-20℃缓慢滴加1mol/L三氟化硼乙醚溶液(0.448mL,0.448mmol),保持-20℃低温反应12h。反应完成后旋干有机相,快速柱层析分离(PE:EA=1:1),得白色固体1.90g,即为化合物AG31,收率为67.4%。1H NMR(500MHz,Chloroform-d)δ6.99(d,J=8.1Hz,1H),6.75(d,J=8.1Hz,1H),6.69(d,J=2.0Hz,1H),6.63(dd,J=8.2,2.0Hz,1H),6.54(dd,J=8.2,2.0Hz,1H),6.49(d,J=2.0Hz,1H),5.25–5.17(m,2H),5.07(d,J=5.7Hz,1H),5.04–4.98(m,1H),4.23(dd,J=12.1,4.7Hz,1H),4.17(dd,J=9.1,7.2Hz,1H),3.91(dd,J=9.1,7.4Hz,1H),3.86(s,3H),3.82(s,3H),3.76(s,3H),3.48–3.45(m,1H),2.99–2.88(m,2H),2.68–2.57(m,2H),2.56–2.44(m,2H),2.11(s,3H),2.09(s,3H),2.08(s,3H).13C NMR(126MHz,CDCl3)δ179.00,170.24,170.05,169.64,150.75,149.01,147.87,144.59,133.96,130.29,121.57,120.59,119.48,113.49,111.88,111.41,100.00,71.44,70.63,70.21,68.65,61.87,55.91,55.91,55.87,46.53,41.05,38.16,34.55,20.79,20.75(2C).HRMS:m/z for C32H38NaO13[M+Na]+calculated:653.2205,found:653.2208.
实施例8
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合AG32:
化合物(2S,3R,4S,5R)-2-(4-(((3R,4R)-4-(3,4-二甲氧基苄基)-2-氧代四氢呋
喃-3-基)甲基)-2-甲氧基苯氧基)四氢-2H-吡喃-3,4,5-三基三(2-甲基丙酸酯)(AG32)的
制备
将化合物AG09(60mg,0.119mmol),吡啶(86.6μL,1.07mmol)加入无水二氯甲烷(2mL)中,N2保护,0℃下逐滴加入异丁酰氯(68.5μL,0.654mmol),滴加完毕后缓慢升至室温反应12h。反应完成后用EA萃取,饱和食盐水洗涤。有机相旋干后快速柱层析分离(PE:EA=1.5:1),得白色固体51mg,即为化合物AG32,收率60.0%。1H NMR(600MHz,Chloroform-d)δ6.99(d,J=8.1Hz,1H),6.75(d,J=8.1Hz,1H),6.69(d,J=2.0Hz,1H),6.63(dd,J=8.1,2.0Hz,1H),6.53(dd,J=8.1,2.0Hz,1H),6.49(d,J=2.0Hz,1H),5.29(t,J=8.4Hz,1H),5.23(dd,J=8.7,6.5Hz,1H),5.08–5.01(m,2H),4.20(dd,J=11.9,5.0Hz,1H),4.14(dd,J=9.1,7.2Hz,1H),3.88(dd,J=9.1,7.6Hz,1H),3.85(s,3H),3.82(s,3H),3.75(s,3H),3.43(dd,J=11.9,8.4Hz,1H),2.99–2.89(m,2H),2.65(dd,J=13.3,5.8Hz,1H),2.60–2.47(m,6H),1.17–1.11(m,18H).13C NMR(151MHz,CDCl3)δ178.62,175.95,175.93,175.37,150.70,149.05,147.91,144.67,133.89,130.31,121.49,120.56,119.44,113.49,111.89,111.40,100.37,71.26,70.78,70.27,68.53,62.30,55.93,55.88,55.79,46.48,41.08,38.14,34.52,33.92(2C),33.88,18.90,18.84,18.82(2C),18.73(2C).HRMS:m/z forC38H50NaO13[M+Na]+calculated:737.3144,found:737.3141.
实施例9
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合AG33:
化合物(3R,4R)-3-(4-(((2R,4aR,6S,7R,8R,8aS)-7,8-二羟基-2-苯基六氢吡喃
[3,2-][1,3]二氧杂环己烷-6-基)氧基)-3-甲氧基苄基)-4-(3,4-二甲氧基苄基)二氢呋
喃-2(3H)-酮(AG33)的制备
将牛蒡子苷(400mg,0.187mmol)溶于乙腈(5mL)中,加入苯甲酸二甲缩醛(225μL,0.374mmol)和(±)-10-樟脑磺酸(2mg,0.002mmol),室温反应12h。反应完成后旋干乙腈,快速柱层析分离(PE:EA=1:2),得白色固体350mg,即为化合物AG33,收率75.1%。1H NMR(500MHz,Chloroform-d)δ7.52–7.46(m,2H),7.37(dd,J=5.2,2.0Hz,3H),7.04(d,J=8.1Hz,1H),6.76(d,J=8.1Hz,1H),6.71(d,J=2.0Hz,1H),6.65(dd,J=8.1,2.0Hz,1H),6.56(dd,J=8.1,2.0Hz,1H),6.49(s,1H),5.56(s,1H),4.79(d,J=7.8Hz,1H),4.37(dd,J=10.5,4.9Hz,1H),4.20(dd,J=9.2,7.4Hz,1H),3.96–3.89(m,2H),3.88–3.74(m,11H),3.64(t,J=9.3Hz,1H),3.53(td,J=9.7,5.0Hz,1H),3.00–2.88(m,2H),2.70–2.57(m,3H),2.55–2.45(m,1H).13C NMR(126MHz,CDCl3)δ178.86,150.45,149.02,147.90,144.69,136.79,134.69,129.84,129.03,128.37,126.27,121.91,120.64,120.37,113.13,111.89,111.40,103.93,102.00,80.19,74.41,73.12,71.43,68.58,66.75,55.93(2C),55.88,46.55,41.01,38.21,34.59.
实施例10
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合AG14和AG15:
中间体四-O-乙酰基-L-吡喃鼠李糖(10-1)的制备
将L-鼠李糖(2g,11mmol)加入吡啶(10mL)中,0℃下缓慢滴加乙酸酐(5.2mL,54.9mmol),升至室温后反应12h。反应完全后浓缩反应液,有机相用EA萃取,1N盐酸和饱和食盐水洗涤。合并有机相后旋干,柱层析分离,得无色透明油状物3.1g,即为中间体10-1,收率76.6%。
化合物(2S,3R,4R,5S,6S)-2-(4-(((3R,4R)-4-(3,4-二甲氧基苄基)-2-氧代四氢
呋喃-3-基)甲基)-2-甲氧基苯氧基)-6-甲基四氢-2H-吡喃-3,4,5-三基三乙酸酯(AG15)的
制备
将牛蒡子苷元(500mg,1.34mmol)和中间体10-1(669mg,2.01mmol)和烘干的分子筛溶于无水DCM(10mL)中,N2保护下缓慢滴加1mol/L的三氟化硼乙醚溶液(111μL,1.01mmol),室温反应12h。反应完成后旋干有机相,快速柱层析分离(PE:EA=1:1),得白色固体285g,即为化合物AG15,收率为32.9%。1H NMR(500MHz,Chloroform-d)δ6.98(d,J=8.1Hz,1H),6.76(d,J=8.1Hz,1H),6.71(d,J=2.0Hz,1H),6.62(dd,J=8.1,2.0Hz,1H),6.54(dd,J=8.1,2.1Hz,1H),6.50(d,J=2.0Hz,1H),5.58–5.49(m,2H),5.34(d,J=1.8Hz,1H),5.15(t,J=9.8Hz,1H),4.22–4.11(m,2H),3.93–3.87(m,1H),3.86(s,3H),3.83(s,3H),3.79(s,3H),3.00–2.89(m,2H),2.68–2.49(m,4H),2.18(s,3H),2.07(s,3H),2.03(s,3H),1.20(d,J=6.3Hz,3H).13C NMR(126MHz,CDCl3)δ178.79,170.15(2C),170.11,150.83,149.02,147.88,144.06,133.78,130.31,121.53,120.55,118.89,113.53,111.86,111.38,97.58,71.32,71.07,69.79,68.99,67.36,55.92,55.88(2C),46.52,41.04,38.15,34.52,20.95,20.84,20.76,17.37.
化合物(3R,4R)-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(((2S,3R,5R,6S)-3,4,
5-三羟基-6-甲基四氢-2H-吡喃-2-基)氧基)苄基)二氢呋喃-2(3H)-酮(AG14)的制备
将化合物AG15(100mg,0.077mmol)溶于甲醇(2mL)中,加入无水碳酸钾(27mg,0.193mmol),室温反应2.5h。反应完成后,旋干有机相,柱层析分离(DCM:MeOH=10:1),得白色固体28mg,即为化合物AG14,收率为69.6%。1H NMR(500MHz,Chloroform-d)δ7.01(d,J=8.1Hz,1H),6.75(d,J=8.1Hz,1H),6.71(d,J=1.9Hz,1H),6.62(dd,J=8.1,2.0Hz,1H),6.55(dd,J=8.1,1.9Hz,1H),6.49(d,J=2.0Hz,1H),5.42(s,1H),4.23(s,1H),4.15(dd,J=9.0,7.1Hz,1H),4.09–3.99(m,1H),3.94–3.86(m,2H),3.86–3.80(m,6H),3.77(s,3H),3.56(t,J=9.3Hz,1H),2.93(qd,J=14.1,5.9Hz,2H),2.67–2.47(m,4H),1.28(d,J=6.2Hz,3H).13C NMR(126MHz,CDCl3)δ178.67,150.40,149.01,147.85,144.26,133.05,130.37,121.63,120.60,118.10,113.35,111.82,111.35,99.20,73.33,71.60,71.30,70.78,68.82,55.92(2C),55.86,46.52,41.07,38.19,34.55,17.45.HRMS:m/z forC27H34NaO10[M+Na]+calculated:541.2044,found:541.2046.
实施例11
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合AG16、AG17、AG24和AG25:
中间体四-O-乙酰基-D-吡喃来苏糖(11-1)的制备
参照中间体10-1的制备方法,以D-来苏糖为起始原料,透明油状物872mg,收率72.3%。1H NMR(500MHz,Chloroform-d)δ6.00(d,J=3.4Hz,1H),5.37(dd,J=9.0,3.5Hz,1H),5.25(t,J=3.4Hz,1H),5.20(td,J=8.9,4.9Hz,1H),4.01(dd,J=11.6,5.0Hz,1H),3.71(dd,J=11.5,8.8Hz,1H),2.16(s,3H),2.14(s,3H),2.08(s,3H),2.06(s,3H).
化合物(2R,3S,4S,5R)-2-(4-(((3R,4R)-4-(3,4-二甲氧基苄基)-2-氧代四氢呋
喃-3-基)甲基)-2-甲氧基苯氧基)四氢-2H-吡喃-3,4,5-三基三乙酸酯(AG17)和化合物
(2S,3S,4S,5R)-2-(4-(((3R,4R)-4-(3,4-二甲氧基苄基)-2-氧代四氢呋喃-3-基)甲基)-
2-甲氧基苯氧基)四氢-2H-吡喃-3,4,5-三基三乙酸酯(AG25)的制备
参照化合物AG15的制备方法,以中间体11-1为起始原料,得α型糖苷与β型糖苷的混合物,经柱层析分离(PE:EA=1.5:1)得118mg白色固体(AG17)与24mg白色固体(AG25),收率分别为53.8%和10.8%。AG17的谱图:1H NMR(500MHz,Chloroform-d)δ6.97(d,J=8.1Hz,1H),6.76(d,J=8.1Hz,1H),6.69(d,J=2.0Hz,1H),6.61(dd,J=8.1,2.0Hz,1H),6.54(dd,J=8.1,2.0Hz,1H),6.50(d,J=2.1Hz,1H),5.57(dd,J=9.8,3.4Hz,1H),5.52(dd,J=3.5,2.3Hz,1H),5.37(d,J=2.4Hz,1H),5.28(td,J=9.8,5.8Hz,1H),4.16(dd,J=9.2,7.3Hz,1H),3.97–3.87(m,3H),3.86(s,3H),3.83(s,3H),3.79(s,3H),2.98–2.87(m,2H),2.67–2.45(m,4H),2.17(s,3H),2.08(s,3H),2.06(s,3H).13C NMR(126MHz,CDCl3)δ179.04,170.35,170.12(2C),150.81,149.00,147.87,143.92,133.87,130.29,121.54,120.59,119.07,113.57,111.87,111.39,97.67,71.44,69.45,68.49,66.78,60.50,55.91,55.89,55.88,46.57,41.01,38.18,34.51,20.87,20.84,20.80.AG25的谱图:1H NMR(500MHz,Chloroform-d)δ6.98(d,J=8.1Hz,1H),6.78(d,J=8.2Hz,1H),6.74(d,J=2.0Hz,1H),6.66(dd,J=8.1,2.0Hz,1H),6.58(dd,J=8.1,2.0Hz,1H),6.52(d,J=2.1Hz,1H),5.46(t,J=3.3Hz,1H),5.43(d,J=3.1Hz,1H),5.30(dd,J=5.9,3.5Hz,1H),5.07(ddd,J=6.0,4.4,3.0Hz,1H),4.34(dd,J=12.6,3.0Hz,1H),4.16(dd,J=9.2,7.2Hz,1H),3.93–3.90(m,1H),3.88(s,3H),3.85(s,3H),3.80(s,3H),3.57(dd,J=12.6,4.4Hz,1H),2.96(dd,J=6.0,1.8Hz,2H),2.71–2.55(m,4H),2.20–2.15(m,6H),2.14(s,3H).13C NMR(126MHz,CDCl3)δ178.81,170.33,170.17,169.94,150.86,149.04,147.89,144.59,133.69,130.34,121.70,120.58,119.41,113.85,111.87,111.39,96.30,71.34,68.37,67.71,67.04,59.97,55.98,55.92,55.86,46.53,41.04,38.16,34.50,20.95,20.84,20.81.
化合物(3R,4R)-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(((2R,3S,4S,5R)-3,4,
5-三羟基四氢-2H-吡喃-2-基)氧基)苄基)二氢呋喃-2(3H)-酮(AG16)的制备
参照化合物AG14的合成方法,以化合物AG17为起始原料,得白色固体28mg,即为化合物AG16,收率58.3%。1H NMR(500MHz,Chloroform-d)δ7.02(d,J=8.1Hz,1H),6.76(d,J=8.1Hz,1H),6.70(d,J=2.0Hz,1H),6.63(dd,J=8.1,1.9Hz,1H),6.56(dd,J=8.1,2.0Hz,1H),6.48(d,J=1.9Hz,1H),5.24(d,J=4.0Hz,1H),4.18–4.13(m,2H),4.12–4.08(m,1H),3.95(tt,J=7.5,3.6Hz,1H),3.91–3.86(m,2H),3.85(s,3H),3.82(s,3H),3.80–3.74(m,4H),2.93(d,J=5.9Hz,2H),2.65(dd,J=13.6,6.5Hz,1H),2.62–2.53(m,2H),2.52–2.44(m,1H).13C NMR(126MHz,CDCl3)δ178.65,150.44,149.03,147.88,144.48,133.62,130.35,121.74,120.63,118.88,113.22,111.83,111.31,100.54,71.39,71.31,69.90,68.06,64.19,55.92,55.89,55.87,46.53,41.04,38.21,34.52.HRMS:m/z forC26H32NaO10[M+Na]+calculated:527.1888,found:527.1890.
化合物(3R,4R)-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(((2S,3S,4S,5R)-3,4,
5-三羟基四氢-2H-吡喃-2-基)氧基)苄基)二氢呋喃-2(3H)-酮(AG24)的制备
参照化合物AG14的合成方法,以化合物AG25为起始原料,得白色固体8mg,即为化合物AG24,收率53.3%。1H NMR(500MHz,Chloroform-d)δ7.00(d,J=7.9Hz,1H),6.81–6.70(m,2H),6.63(d,J=7.9Hz,1H),6.56(d,J=8.0Hz,1H),6.49(s,1H),5.43(s,1H),4.22–4.08(m,3H),4.05–3.95(m,2H),3.93–3.88(m,1H),3.86(s,3H),3.84–3.78(m,6H),3.54(d,J=12.8Hz,1H),2.94(d,J=5.4Hz,2H),2.72–2.41(m,4H).13C NMR(126MHz,CDCl3)δ178.55,150.11,149.07,147.94,143.82,133.60,130.30,121.71,120.61,117.36,112.80,111.85,111.36,100.10,71.66,71.29,69.88,65.60,60.61,55.94(2C),55.89,46.55,41.04,38.22,34.53.
实施例12
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合AG18和AG19:
中间体四-O-乙酰基-D-吡喃来苏糖(12-1)的制备
参照中间体10-1的制备方法,以D-阿拉伯糖为起始原料,得透明油状物3.9g,即为中间体12-1,收率76.5%。
化合物(2R,3S,4R,5R)-2-(4-(((3S,4S)-4-(3,4-二甲氧基苄基)-2-氧代四氢呋
喃-3-基)甲基)-2-甲氧基苯氧基)四氢-2H-吡喃-3,4,5-三基乙酸酯(AG19)的制备
参照化合物AG15的制备方法,以中间体12-1为起始原料,得白色固体99mg,即为化合物AG19,收率16.5%。1H NMR(500MHz,Chloroform-d)δ6.94(d,J=8.1Hz,1H),6.79(d,J=8.1Hz,1H),6.73(d,J=2.0Hz,1H),6.65(dd,J=8.1,2.0Hz,1H),6.58(dd,J=8.1,2.1Hz,1H),6.52(d,J=2.0Hz,1H),5.71(d,J=3.5Hz,1H),5.61(dd,J=10.9,3.5Hz,1H),5.47(dd,J=3.6,1.9Hz,1H),5.29(dd,J=10.9,3.6Hz,1H),4.32(dd,J=13.1,1.4Hz,1H),4.17(dd,J=9.1,7.3Hz,1H),3.93–3.87(m,4H),3.85(s,3H),3.79(s,3H),3.76(d,J=1.3Hz,1H),2.96(d,J=6.0Hz,2H),2.69–2.52(m,4H),2.19(s,3H),2.15(s,3H),2.07(s,3H).13C NMR(126MHz,CDCl3)δ178.74,170.67,170.47,170.16,151.08,149.05,147.91,144.18,134.06,130.30,121.66,120.58,119.98,113.58,111.84,111.39,96.94,71.31,69.07,68.32,67.07,61.27,55.92,55.86,55.78,46.50,41.02,38.16,34.48,20.97,20.85,20.78.
化合物(3R,4R)-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(((2R,3S,4R,5R)-3,4,
5-三羟基四氢-2H-吡喃-2-基)氧基)苄基)二氢呋喃-2(3H)-酮(AG18)的制备
参照化合物AG14的合成方法,以AG15为起始原料,得19mg白色固体,即为化合物AG18,收率79.2%。1H NMR(500MHz,Chloroform-d)δ7.07(d,J=8.1Hz,1H),6.76(d,J=8.1Hz,1H),6.72(d,J=2.1Hz,1H),6.63(dd,J=8.1,2.0Hz,1H),6.57(dd,J=8.1,2.1Hz,1H),6.50(d,J=2.0Hz,1H),5.29(d,J=3.7Hz,1H),4.19–4.08(m,3H),4.04(dd,J=9.6,3.4Hz,1H),3.94–3.87(m,3H),3.86(s,3H),3.83(s,3H),3.81(s,3H),2.94(dt,J=7.1,4.1Hz,2H),2.66(dd,J=13.7,6.5Hz,1H),2.61–2.55(m,2H),2.51–2.43(m,1H).13C NMR(126MHz,CDCl3)δ178.56,150.60,149.06,147.93,145.27,134.04,130.29,121.95,120.60,119.65,112.81,111.82,111.36,101.53,71.26,70.66,69.72,68.76,63.27,55.92,55.86,55.77,46.52,40.98,38.17,34.48.HRMS:m/z for C26H32NaO10[M+Na]+calculated:527.1888,found:527.1891.
实施例13
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合AG20和AG21:
中间体(2S,3S,4S,5R,6S)-2-(碘甲基)-6-甲氧基四氢-2H-吡喃-3,4,5-三醇(13-
1)的制备
将甲基α-D-吡喃葡萄糖苷(3g,15.45mmol),三苯基膦(6.08g,23.17mmol)和咪唑(2.10g,30.90mmol)溶于乙腈(30ml)中,分批加入碘颗(4.9g,19.31mmol),加入完毕后升温至70℃反应10h。反应完成后加入三乙胺(3.1mL)淬灭反应,浓缩除去乙腈。向反应混合物中加入水(6mL)于45℃搅拌45min,继续加入水(24mL)搅拌1h,有白色固体析出。抽滤,收集滤液,并将白色固体用水充分洗涤以收集固体中的残留糖液,合并滤液即为中间体13-1的水溶液。不经纯化直接将13-1的水溶液用于下一步反应。
中间体(2S,3R,4S,5S,6R)-2-甲氧基-6-甲基四氢-2H-吡喃-3,4,5-三醇(13-2)的
制备
将中间体13-1的水溶液使用N2保护,后加入次亚磷酸钙(1.14g,10.82mmol)与VA-044(500mg,1.55mmol),升温至70℃反应1.5h。反应完成后冷却至室温,加入氢氧化钙(494mg,8.5mmol)搅拌30min使钙盐沉淀。滤出不溶性沉淀后,旋干滤液,得粗产物13-2,直接用于下一步反应。
中间体(2S,3R,4S,5R,6R)-2-甲氧基-6-甲基四氢-2H-吡喃-3,4,5-三乙酸三酯
(13-3)的制备
向中间体13-2中加入乙腈(15mL),0℃下加入乙酸酐(8mL,84mmol),三乙胺(11.7mL,84mmol)和二甲氨基吡啶(68mg,0.56mmol),缓慢升至室温后反应12h。反应完成后浓缩反应液,乙酸乙酯萃取,先后用饱和碳酸氢钠、饱和亚硫酸钠和饱和食盐水洗涤。有机相旋干后柱层析分离(PE:EA=4:1),得无色透明油状物2.2g,即为中间体13-3,收率46.9%。1H NMR(500MHz,Chloroform-d)δ5.47–5.41(m,1H),4.91–4.84(m,2H),4.80(t,J=9.6Hz,1H),3.92–3.86(m,1H),3.40(s,3H),2.08(s,3H),2.04(s,3H),2.01(d,J=1.0Hz,3H),1.20(d,J=6.3Hz,3H).
中间体1,2,3,4-四-O-乙酰基-6-脱氧-α/β-D-吡喃葡萄糖(13-4)的制备
0℃下,将13-3(1.5g,4.93mmol)溶于冰醋酸(935μL)中,加入等体积乙酸酐(935μL,9.86mmol),逐滴加入浓硫酸(40μL,0.074mmol),升至室温反应3h。反应完成后,冷却至0℃,用饱和碳酸氢钠调pH至近中性,EA萃取,有机相用饱和食盐水洗涤,旋干有机相,柱层析(PE:EA=5:1)得白色固体1g,即为化合物13-4,为α和β构型混合物,收率61.1%。α异构型谱图:1H NMR(500MHz,Chloroform-d)δ6.21(d,J=3.7Hz,1H),5.41–5.35(m,1H),5.01(dd,J=10.3,3.7Hz,1H),4.82–4.78(m,1H),3.95(dq,J=10.0,6.2Hz,1H),2.00(s,3H),1.97(s,3H),1.95(s,3H),1.15(d,J=6.2Hz,3H).
中间体(3R,4S,5R,6R)-2-羟基-6-甲基四氢-2H-吡喃-3,4,5-三乙酸三酯(13-5)
的制备
将中间体13-4(550mg,1.65mmol)溶于四氢呋喃(5mL)后,加入乙酸肼(167mg,1.83mmol),升温至50℃反应1.5h。反应完成后直接旋干,柱层析分离(PE:EA=1:1),得白色固体190mg,即为中间体13-5,收率39.6%。1H NMR(500MHz,Chloroform-d)δ5.51(dd,J=10.2,9.5Hz,1H),5.42(t,J=3.5Hz,1H),4.91(dd,J=10.1,3.7,1H),4.86–4.82(m,1H),4.17–4.11(m,1H),2.93(dd,J=3.5,1.2Hz,1H),2.10(s,3H),2.07(s,3H),2.04(s,3H),1.21(d,J=6.3Hz,3H).
中间体(2R,3R,4S,5R)-2-甲基-6-(((三氯甲基)氨基)氧基)四氢-2H-吡喃-3,4,
5-三乙酸酯(13-6)的制备
将中间体13-5(190mg,0.66mmol)溶于无水二氯甲烷中,N2保护并降温至0℃,加入DBU(31.2μL,0.21mmol),反应5min后逐滴加入三氯乙腈(197μL,1.96mmol),缓慢升至室温反应12h。反应完成后直接旋干,柱层析分离(PE:EA=20:1)得260mg黄色固体,即为中间体13-6,收率92.9%。1H NMR(500MHz,Chloroform-d)δ8.64(s,1H),6.49(d,J=3.7Hz,1H),5.53(t,J=9.9Hz,1H),5.10(dd,J=10.2,3.8Hz,1H),4.93–4.86(m,1H),4.16–4.08(m,1H),2.06(s,3H),2.03(s,3H),2.01(s,3H),1.23(d,J=6.2Hz,3H).
化合物(2R,3R,4S,5R,6R)-2-(4-(((3R,4R)-4-(3,4-二甲氧基苄基)-2-氧代四氢
呋喃-3-基)甲基)-2-甲氧基苯氧基)-6-甲基四氢-2H-吡喃-3,4,5-三基三乙酸酯(AG21)的
制备
将牛蒡子苷元(110mg,0.295mmol),中间体13-6(128mg,0.295mmol)和分子筛加入无水二氯甲烷(5mL)中,N2保护,0℃下缓慢加入三氟甲磺酸三甲基硅酯(8μL,0.004mmol),缓慢升至室温反应12h。反应完成后快速柱层析(PE:EA=1:1)得白色固体23mg,即为化合物AG21,收率12.1%。1H NMR(500MHz,Chloroform-d)δ6.91(d,J=8.0Hz,1H),6.77(d,J=8.2Hz,1H),6.71(d,J=2.0Hz,1H),6.62(dd,J=8.1,2.0Hz,1H),6.55(dd,J=8.1,2.0Hz,1H),6.51(d,J=2.1Hz,1H),5.68(dd,J=10.3,9.4Hz,1H),5.59(d,J=3.7Hz,1H),4.95(dd,J=10.3,3.8Hz,1H),4.87(t,J=9.7Hz,1H),4.30(dt,J=10.0,6.3Hz,1H),4.15(dd,J=9.2,7.4Hz,1H),3.91–3.85(m,4H),3.84(s,3H),3.76(s,3H),2.99–2.90(m,2H),2.67(dd,J=13.6,6.2Hz,1H),2.63–2.53(m,2H),2.48(dt,J=15.8,7.8Hz,1H),2.11(s,3H),2.08(s,3H),2.05(s,3H),1.18(d,J=6.3Hz,3H).13C NMR(126MHz,CDCl3)δ178.93,170.50,170.39,170.10,151.14,149.05,147.92,144.20,134.20,130.31,121.69,120.58,120.43,113.73,111.88,111.42,96.11,73.78,71.36,71.24,69.93,66.09,55.93,55.90,55.82,46.56,40.96,38.13,34.40,20.79,20.76,20.76,17.12.
化合物(3R,4R)-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(((2R,3R,4S,5S,6R)-
3,4,5-三羟基-6-甲基四氢-2H-吡喃-2-基)氧基)苄基)二氢呋喃-2(3H)-酮(AG20)的制备
参照化合物AG14的制备方法,以AG21为起始原料,得白色固体24mg,即为化合物AG20,收率80.6%。1H NMR(500MHz,Chloroform-d)δ6.99(d,J=8.1Hz,1H),6.70(d,J=8.1Hz,1H),6.63(d,J=2.0Hz,1H),6.58(dd,J=8.1,2.0Hz,1H),6.50(dd,J=8.2,2.0Hz,1H),6.42(d,J=2.0Hz,1H),5.13(d,J=3.8Hz,1H),4.10(dd,J=9.2,7.4Hz,1H),3.95(dq,J=9.6,6.3Hz,1H),3.87–3.81(m,2H),3.79(s,3H),3.76(s,3H),3.73(s,3H),3.53(dd,J=9.5,3.8Hz,1H),3.23(t,J=9.3Hz,1H),2.93–2.83(m,2H),2.62–2.56(m,1H),2.55–2.47(m,2H),2.45–2.38(m,1H),1.27(d,J=6.3Hz,3H).13C NMR(126MHz,CDCl3)δ178.56,150.63,149.05,147.91,145.27,134.06,130.31,121.87,120.61,119.74,112.80,111.81,111.32,100.93,75.17,74.88,72.73,71.28,68.55,55.92,55.87,55.78,46.53,41.01,38.22,34.58,17.53.HRMS:m/z for C27H34NaO10[M+Na]+calculated:541.2044,found:541.2051.
实施例14
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合AG22和AG23:
中间体14-1至14-6的合成参照中间体13-1至13-6的合成方法,以α-甲基-D-甘露糖苷为起始原料。
化合物(2R,3S,4S,5R,6R)-2-(4-(((3R,4R)-4-(3,4-二甲氧基苄基)-2-氧代四氢
呋喃-3-基)甲基)-2-甲氧基苯氧基)-6-甲基四氢-2H-吡喃-3,4,5-三基三乙酸酯(AG23)的
制备
参照化合物AG21的制备方法,以中间体14-1为起始原料,得白色固体150mg,即为化合物AG23,收率76.7%。1H NMR(500MHz,Chloroform-d)δ6.97(d,J=8.1Hz,1H),6.75(d,J=8.1Hz,1H),6.69(d,J=2.0Hz,1H),6.63(dd,J=8.1,2.0Hz,1H),6.53(dd,J=8.1,2.1Hz,1H),6.50(d,J=2.0Hz,1H),5.57–5.50(m,2H),5.35(d,J=1.8Hz,1H),5.14(t,J=9.9Hz,1H),4.21–4.10(m,2H),3.91–3.85(m,4H),3.83(s,3H),3.79(s,3H),3.00–2.88(m,2H),2.67–2.45(m,4H),2.18(s,3H),2.07(s,3H),2.02(s,3H),1.19(d,J=6.3Hz,3H).
化合物(3R,4R)-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(((2R,3S,4S,5S,6R)-
3,4,5-三羟基-6-甲基四氢-2H-吡喃-2-基)氧基)苄基)二氢呋喃-2(3H)-酮(AG22)的制备
参照化合物AG14的制备方法,以化合物AG23为起始原料,得白色固体60mg,即为化合物AG22,收率74.6%。1H NMR(500MHz,Chloroform-d)δ7.00(d,J=8.1Hz,1H),6.75(d,J=8.1Hz,1H),6.69(d,J=2.0Hz,1H),6.63(dd,J=8.1,2.0Hz,1H),6.55(dd,J=8.2,2.0Hz,1H),6.49(d,J=2.0Hz,1H),5.42(d,J=1.6Hz,1H),4.23(dd,J=3.5,1.7Hz,1H),4.18–4.10(m,1H),4.10–4.01(m,1H),3.89(ddd,J=14.3,9.3,6.8Hz,2H),3.84(s,3H),3.82(s,3H),3.76(s,3H),3.58(q,J=9.9,9.4Hz,1H),2.99–2.86(m,2H),2.67–2.45(m,4H),1.27(d,J=6.3Hz,3H).13C NMR(126MHz,CDCl3)δ178.68,150.46,149.01,147.86,144.25,133.12,130.37,121.64,120.61,118.23,113.32,111.84,111.36,99.34,73.22,71.58,71.29,70.80,68.90,55.91(2C),55.88,46.52,41.11,38.17,34.55,17.46.
实施例15
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合AG26:
化合物(3R,4R)-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(((2S,3R,4S,5R)-3,4,
5-三甲氧基四氢-2H-吡喃-2-基)氧基)苄基)二氢呋喃-2(3H)-酮(AG26)的制备
将化合物AG09(60mg,0.119mmol)与2,6-二叔丁基吡啶(252μL,1.14mmol)溶于1,2-二氯乙烷(2mL)中,升温至70℃反应2h。反应完成后直接旋干,柱层析分离(PE:EA=2:1)得白色固体16mg,即为化合物AG26,收率24.6%。1H NMR(500MHz,Chloroform-d)δ6.98(d,J=8.1Hz,1H),6.75(d,J=8.1Hz,1H),6.71(d,J=2.0Hz,1H),6.63(dd,J=8.2,2.0Hz,1H),6.54(dd,J=8.1,2.0Hz,1H),6.49(d,J=2.0Hz,1H),4.84(d,J=7.2Hz,1H),4.14(dd,J=9.2,7.1Hz,1H),4.05(dd,J=11.7,5.0Hz,1H),3.90–3.86(m,1H),3.86(s,3H),3.82(s,3H),3.80(s,3H),3.68(s,3H),3.64(s,3H),3.48(s,3H),3.38–3.30(m,2H),3.27–3.20(m,2H),2.99–2.90(m,2H),2.66(dd,J=13.0,5.5Hz,1H),2.62–2.52(m,2H),2.51–2.46(m,1H).13C NMR(126MHz,CDCl3)δ178.69,150.34,149.03,147.87,145.46,132.95,130.37,121.53,120.56,117.73,113.31,111.86,111.36,102.94,84.66,82.92,79.15,71.26,63.20,60.62,60.46,58.66,55.98,55.91,55.86,46.51,41.00,38.16,34.49.HRMS:m/zfor C29H28NaO10[M+Na]+calculated:569.2357,found:569.2365.
实施例16
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合AG27和AG28:
化合物(2S,3R,4S,5R,6R)-2-(4-((((3R,4R)-4-(3,4-二甲氧基苄基)-2-氧代四
氢呋喃-3-基)甲基)-2-甲氧基苯氧基)-6-甲基四氢-2H-吡喃-3,4,5-三基三乙酸酯(AG28)
的制备:
将牛蒡子苷元(100mg,0.268mmol),中间体13-6(123mg,0.282mmol)和分子筛加入无水二氯甲烷(5mL)中,N2保护,0℃下缓慢加入三氟化硼乙醚(7μL,0.054mmol),缓慢升至室温反应12h。反应完成后旋干,快速柱层析分离(PE:EA=1:1),得白色固体86mg,即为化合物AG28,收率49.7%。1H NMR(500MHz,Chloroform-d)δ7.01(d,J=8.0Hz,1H),6.75(d,J=8.1Hz,1H),6.67(d,J=2.0Hz,1H),6.64(dd,J=8.1,2.0Hz,1H),6.53(dd,J=8.1,2.0Hz,1H),6.48(d,J=2.0Hz,1H),5.26–5.22(m,2H),4.96–4.88(m,2H),4.17(dd,J=9.1,7.2Hz,1H),3.90(dd,J=9.1,7.3Hz,1H),3.85(s,3H),3.82(s,3H),3.75(s,3H),3.63(dq,J=9.8,6.2Hz,1H),2.99–2.87(m,2H),2.65–2.48(m,4H),2.07(s,3H),2.05(s,3H),2.03(s,3H),1.27(d,J=6.2Hz,3H).13C NMR(126MHz,CDCl3)δ178.80,170.51,169.78,169.59,150.77,149.02,147.88,145.09,134.12,130.27,121.52,120.56,119.88,113.55,111.88,111.40,100.62,73.27,72.69,71.65,71.38,70.22,55.98,55.93,55.88,46.50,41.08,38.18,34.61,20.70(3C),17.44.HRMS:m/z for C33H40NaO13[M+Na]+calculated:667.2361,found:667.2366.
化合物(3R,4R)-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(((2S,3R,4S,5S,6R)-
3,4,5-三羟基-6-甲基四氢-2H-吡喃-2-基)氧基)苄基)二氢呋喃-2(3H)-酮(AG27)的制备:
参照化合物AG14的制备方法,以AG28为起始原料,得白色固体28mg,即为化合物AG27,收率68.2%。1H NMR(500MHz,Chloroform-d)δ7.04(d,J=8.0Hz,1H),6.75(d,J=8.1Hz,1H),6.69(d,J=1.9Hz,1H),6.64(dd,J=8.1,1.9Hz,1H),6.54(dd,J=8.0,1.9Hz,1H),6.48(d,J=2.0Hz,1H),4.66(d,J=7.5Hz,1H),4.22–4.13(m,1H),3.93–3.87(m,1H),3.85(s,3H),3.81(s,3H),3.80(s,3H),3.59(dt,J=28.3,9.0Hz,2H),3.51–3.41(m,1H),3.31(t,J=8.8Hz,1H),3.00–2.88(m,2H),2.69–2.63(m,1H),2.61–2.53(m,2H),2.52–2.47(m,1H),1.38(d,J=6.0Hz,3H).13C NMR(126MHz,CDCl3)δ178.58,150.26,149.02,147.89,145.06,134.04,130.27,121.90,120.61,119.58,113.01,111.86,111.37,103.13,76.31,74.93,73.81,72.19,71.30,55.93(2C),55.89,46.51,40.98,38.20,34.55,17.70.HRMS:m/z for C27H34NaO10[M+Na]+calculated:541.2044,found:541.2054.
实施例17
本实施例中,按照上述反应式,制备本发明的二苄基丁内酯糖苷类化合AG29和AG30:
中间体6-溴-6-脱氧-1,2:3,5-二-O-异亚丙基-α-D-呋喃葡萄糖(15-1)的制备
0℃下,将NBS(6.8g,38.42mmol)溶于DMF(140mL),加入三苯基膦(9.8g,37.46mmol)反应10min,后加入二丙酮-D-葡萄糖(5g,19.21mmol)反应3h,并升温至105℃继续反应2h。反应完成后,浓缩反应液,用EA萃取,有机相用5%碳酸氢钠、饱和食盐水洗涤。旋干有机相,柱层析分离(PE:EA=10:1)得无水油状物3.5g,即为中间体15-1,收率56.4%。1HNMR(500MHz,Chloroform-d)δ6.00(d,J=3.7Hz,1H),4.59(d,J=3.6Hz,1H),4.33(dd,J=7.2,3.9Hz,1H),4.24(d,J=3.9Hz,1H),3.74(td,J=7.3,3.3Hz,1H),3.62(dd,J=10.9,3.2Hz,1H),3.44(dd,J=10.9,7.4Hz,1H),1.50(s,3H),1.39(s,3H),1.37(s,3H),1.33(s,3H).
中间体(3aR,3bS,7aS,8aR)-2,2,5,5-四甲基-7-亚甲基四氢-7H-[1,3]二氧杂环
[4',5':4,5]呋喃[3,2-d][1,3]二恶英(15-2)的制备
将中间体15-1(3.52g,10.89mmol)溶于甲苯(22mL)中,加入DBU(3.25mL,21.78mmol),升温至80℃反应12h。反应完成后,滤出白色沉淀,将滤液旋干,柱层析分离(PE:EA=10:1)得无色油状物2.3g,即为中间体15-2,收率87.16%。1H NMR(500MHz,Chloroform-d)δ6.01(t,J=4.0Hz,1H),4.79(d,J=0.9Hz,1H),4.71(d,J=0.9Hz,1H),4.61–4.56(m,1H),4.42–4.35(m,2H),1.55(s,3H),1.50(s,3H),1.42(s,3H),1.35(s,3H).
中间体脱氧-1,2:3,5-二-O-异亚丙基-L-呋喃艾杜糖(15-3)的制备
将中间体15-2(2g,8.26mmol)溶于乙醇(30mL)中,加入10%钯碳(200mg),氢气氛围下反应18h。反应完成后,滤出固体,滤液旋干后柱层析分离(PE:EA=20:1),得无色透明油状物888mg,即为中间体15-3,收率44.03%。
中间体2,3,4-四-O-乙酰基-6-脱氧-L-吡喃艾杜糖(15-4)的制备
将中间体15-3(888mg,3.64mmol)和15离子交换树脂(320mg)加入水(10mL)中,回流反应18h。反应完成后,冷却至室温,抽滤,将滤液分别用乙醇与甲苯共沸,得黄色油状物。将黄色油状物溶于吡啶(8mL)中,0℃下缓慢滴加乙酸酐,滴加完毕后缓慢升至室温反应18h。反应完成后,反应液用EA萃取,饱和食盐水洗涤,旋干有机相后柱层析分离(PE:EA=3:1),得无色油状物662mg,即为中间体15-4,收率54.8%。
化合物(2S,3R,4S,5R,6S)-2-(4-((((3R,4R)-4-(3,4-二甲氧基苄基)-2-氧代四
氢呋喃-3-基)甲基)-2-甲氧基苯氧基)-6-甲基四氢-2H-吡喃-3,4,5-三基三乙酸酯(AG30)
的制备
参照化合物AG31的制备方法,以中间体15-4为起始原料,得白色固体30mg,即为化合物AG30,收率15.8%。1H NMR(500MHz,Chloroform-d)δ7.01(d,J=8.1Hz,1H),6.78(d,J=8.1Hz,1H),6.74(d,J=2.0Hz,1H),6.65(dd,J=8.2,2.0Hz,1H),6.58(dd,J=8.1,2.0Hz,1H),6.53(d,J=2.0Hz,1H),5.45(dd,J=2.2,0.9Hz,1H),5.17(ddd,J=4.3,2.2,0.7Hz,1H),5.11–5.06(m,1H),4.91–4.86(m,1H),4.58(qd,J=6.5,2.2Hz,1H),4.17–4.12(m,1H),3.92–3.89(m,1H),3.88(s,3H),3.85(s,3H),3.80(s,3H),2.97(d,J=5.9Hz,2H),2.68–2.51(m,4H),2.18(s,3H),2.17(s,3H),2.15(s,3H),1.19(d,J=6.6Hz,3H).13C NMR(126MHz,CDCl3)δ178.86,170.22,169.58,169.37,150.51,149.04,147.89,144.49,132.94,130.38,121.61,120.58,117.64,113.44,111.87,111.40,97.23,71.32,69.43,67.80,66.96,63.40,55.93,55.87(2C),46.56,41.05,38.14,34.48,20.89,20.80,20.76,15.60.HRMS:m/z for C33H40NaO13[M+Na]+calculated:667.2361,found:667.2368.
化合物(3R,4R)-4-(3,4-二甲氧基苄基)-3-(3-甲氧基-4-(((2S,3R,4S,5S,6S)-
3,4,5-三羟基-6-甲基四氢-2H-吡喃-2-基)氧基)苄基)二氢呋喃-2(3H)-酮(AG29)的制备
参照化合物AG14的制备方法,以AG30为起始原料,得白色固体22mg,即为化合物AG29,收率72.3%。1H NMR(500MHz,Chloroform-d)δ7.00(d,J=8.1Hz,1H),6.79–6.72(m,2H),6.64(dd,J=8.2,2.0Hz,1H),6.56(dd,J=8.2,2.0Hz,1H),6.50(d,J=2.0Hz,1H),5.59(s,1H),4.26(qd,J=6.6,1.6Hz,1H),4.14(dd,J=9.1,7.2Hz,1H),4.05(d,J=4.2Hz,1H),3.95(p,J=1.5Hz,1H),3.89(dd,J=9.1,7.7Hz,1H),3.86(s,3H),3.83(s,3H),3.80(s,3H),3.69–3.65(m,1H),3.00–2.90(m,2H),2.67–2.44(m,4H),1.18(d,J=6.7Hz,3H).13CNMR(126MHz,CDCl3)δ178.62,149.85,149.05,147.91,142.71,132.85,130.35,121.49,120.59,116.03,112.78,111.84,111.36,99.19,71.78,71.28,69.44,67.87,63.38,55.93,55.86,55.80,46.53,41.14,38.19,34.60,15.92.HRMS:m/z for C27H34NaO10[M+Na]+calculated:541.2044,found:541.2053.
实施例18、通过本发明所述制备方法,实现了本发明化合物的立体选择性制备
牛蒡子苷β-D-木糖衍生物(即,化合物AG09)的立体选择性制备:
步骤一:将牛蒡子苷元(2.5g,6.71mmol)和1,2,3,4-四-O-乙酰-β-D-吡喃木糖(1.42g,4.48mmol)溶于无水DCM(50mL)中,N2保护,-20℃下缓慢滴加1mol/L三氟化硼乙醚溶液(0.448mL,0.448mmol),保持-20℃低温反应12h。反应完成后,旋干有机相,快速柱层析分离(PE:EA=1:1),得上式所示中间体化合物,其为白色固体,产量为1.90g,收率为67.4%。1H NMR(500MHz,Chloroform-d)δ7.02(d,J=8.1Hz,1H),6.78(d,J=8.1Hz,1H),6.72(d,J=2.0Hz,1H),6.66(dd,J=8.2,2.0Hz,1H),6.56(dd,J=8.1,2.0Hz,1H),6.51(d,J=2.1Hz,1H),5.28–5.20(m,2H),5.09(d,J=5.7Hz,1H,1-H),5.03(td,J=7.5,4.7Hz,1H),4.25(dd,J=12.1,4.7Hz,1H),4.18(dd,J=9.1,7.2Hz,1H),3.91(dd,J=9.1,7.6Hz,1H),3.88(s,3H),3.85(s,3H),3.79(s,3H),3.48(dd,J=12.1,7.8Hz,1H),3.02–2.91(m,2H),2.67(dd,J=13.4,6.0Hz,1H),2.64–2.54(m,2H),2.53–2.46(m,1H),2.13(s,3H),2.11(s,3H),2.10(s,3H).
步骤二:参照AG02的制备方法,由步骤一所得中间体化合物制得白色固体1.55g,收率68.6%。产物经NMR与MS确证为单一的、具有β-糖苷键的化合物8(AG09)。
实施例19、本发明化合物对PDE4的抑制活性
本实施例中,将编码人源PDE4D催化结构域的cDNA序列(GenBank:NM_001197221.1;coding region:T86-S413)克隆到表达载体pET15b中,转化至Escherichiacoli BL21(DE3)表达菌株,16℃低温诱导目的蛋白表达。5000转/分钟室温收集菌体后,重悬经高压破碎,以12000转/每分钟离心45min后取上清。通过Ni-NTA亲和层析柱,经50mMNaH2PO4(pH 7.5)、200mM NaCl和50mM Imidazole的缓冲液洗柱后,以含200mM咪唑的缓冲液洗脱得到目的蛋白后。进一步由阴离子亲和层析和分子排阻层析逐步获得高纯度目的蛋白PDE4D催化结构域(纯度>95%),用于后续实验。
1.抑制PDE4D的IC50测定
采用临近闪烁实验(Scintillation Proximity Assay,SPA)方法测定本发明的一系列化合物(AG03、AG04、AG06、AG08、AG09、AG10)和阳性对照化合物Arctiin(AG01)对PDE4D催化结构域的酶活抑制效果(即,IC50值)。在实验中,使用分析缓冲液(50mM Tris pH 7.5、8.3mM MgCl2和1.7mM EGTA)制备浓度为0.2-0.4nM的蛋白质溶液。在总体积为125μL/孔的96孔板中进行反应。将待测化合物溶解在DMSO(最终浓度为1%(v/v))中,设置一系列浓度梯度,并将其以10μL的体积添加到板中,然后添加80μL蛋白质溶液和10μL[3H]-cAMP(0.5μCi/mL)。在30℃下孵育10分钟后,通过添加25μL磷酸二酯酶SPA珠(RPNQ0150,PerkinellerInc.)终止反应,适当振摇,静置20min后,使用微孔板闪烁计数器读数。并将抑制活性达50%时抑制剂的浓度定为IC50值。实验设至少2个复孔。
实验结果如表1所示。
表1本发明化合物对PDE4D的抑制活性
表1结果表明,本发明化合物对PDE4D具有强烈的抑制作用,显著优于阳性化合物Arctiin(AG01)。
特别是,化合物AG09对PDE4D的半抑制浓度曲线如图1所示,由图1可知,化合物AG09对PDE4D的半抑制浓度(IC50值)可达百纳摩尔,相较于阳性化合物Arctiin(AG01)提高了21倍之多。
2.在特定浓度下对于PDE4D的抑制率测定
采用与上述测定IC50值基本相同的方法(除了将待测化合物终浓度分别调整为5μM和0.5μM),分别测定5μM和0.5μM下,本发明化合物AG15、AG17、AG26、AG27、AG28、AG29、AG31、AG32、AG33和阳性对照化合物Arctiin(AG01)对PDE4的抑制率。对PDE4D的抑制率的计算公式如下:
抑制率=(对照组吸光度值-测试组吸光度值)/(对照组吸光度值-空白组吸光度值)×100%
实验结果如表2所示。
表2特定浓度下本发明化合物对PDE4D的抑制率
表2结果表明,本发明化合物对PDE4D具有极高的抑制率,特别是在5μM下,其抑制率均在90%以上,最高可达99.93%,接近100%;此外,无论在5μM还是在0.5μM下,本发明化合物对PDE4D的抑制率均显著优于阳性化合物Arctiin(AG01)。
结论:
以上结果表明,本发明化合物对PDE4D具有极高的抑制活性;由于PDE4D与PDE4A、PDE4B、PDE4C的催化结构域具有非常高的序列同一性,因此,可由上述结果获知,本发明化合物对PDE4A、PDE4B、PDE4C也均具有较高的抑制活性。
实施例20、本发明化合物对PBMC中TNF-α分泌的影响
PDE4广泛表达于免疫和炎症相关细胞,如中性粒细胞、嗜酸性粒细胞和单核细胞,使PDE4成为免疫及炎症相关疾病中主要的抗炎药物研究的重要靶点。PDE4通过调节cAMP信号通路水平,改变炎症介质的表达,如TNF-α、干扰素-γ、IL-6和IL-12。脂多糖(Lipopolysaccharide,LPS)是革兰氏阴性菌胞壁的成份,可通过MAPK等多种信号通路显著激发致炎因子TNF-α的表达,从而评价PDE4部分抑制剂的细胞活性,模拟体外炎症效应。PDE4部分抑制剂对人PBMC细胞TNF-α表达的抑制效应主要参照George W.Muller等人的工作。
将冻存的人PBMC细胞解冻后,离心收集细胞沉淀,以6*106个/mL重新悬浮在含有RPMI1640和10% FBS新鲜培养基的96孔板中,并在37℃,5% CO2恒温箱中孵育3-4h。将梯度浓度的待测化合物(包括本发明的化合物AG04、AG06、AG08、AG09、AG10和阳性对照化合物Arctiin(AG01))加入人PBMC中,确保每孔DMSO的终浓度为0.1%。于37℃,5% CO2恒温箱中孵育1-1.5h。加入终浓度为1μg/mL的LPS,于37℃,5% CO2中孵育24h刺激细胞产生细胞因子。设置无刺激剂本底对照及刺激对照孔,总体积为200μl,DMSO终浓度为0.1%。收集上清液,用hTNF-αELISA试剂盒测定化合物对人PBMC细胞分泌TNF-α的抑制活性。使用GraphPadPrism 8.0版(GraphPad Inc.)对测定数据进行分析。化合物对人PBMC细胞分泌TNF-α的抑制活性以其对TNF-α分泌的半抑制浓度(即EC50值)表示。
此外,采用与上述测定EC50值基本相同的方法(除了将待测化合物终浓度分别调整为50μM和10μM),测试了上述本发明化合物在50μM、10μM下对人PBMC细胞中炎症因子TNF-α分泌的抑制率。TNF-α采用双波长测定吸光值,以排除单波长检测时的测定干扰,经酶标仪分别检测OD450nm和OD570nm光度值(OD450nm为检测波长;OD570nm为参考波长)。得到的原始数据消除非特异性吸收(OD450nm-OD570nm)并根据标准曲线拟合公式转换成相应浓度后,再计算抑制率。化合物对人PBMC细胞分泌TNF-α的抑制率的计算公式如下:
TNF-α抑制率%=(对照组吸光度值-测试组吸光度值)/(对照组吸光度值-空白组吸光度值)×100%。
各待测化合物对人PBMC细胞中炎症因子TNF-α分泌的抑制实验结果如表3所示。
表3化合物对PBMC细胞中炎症因子TNF-α分泌的抑制实验结果
表3结果表明,本发明的一系列化合物AG04、AG06、AG08、AG09、AG10均表现出显著的抑制人PBMC细胞分泌TNF-α的效应,特别是,在50μM浓度下,它们可以明显抑制人PBMC中TNF-α的分泌,其对人PBMC分泌TNF-α的抑制率远远高于阳性对照化合物AG01。
并且,本发明化合物AG04、AG06、AG08、AG09、AG10抑制PBMC细胞分泌TNF-α的EC50值在3.51-24.04μM范围内,而阳性化合物AG01的EC50值则高达97.58μM,表明其对PBMC细胞分泌TNF-α的抑制效应显著弱于本发明的一系列化合物。
特别是,化合物AG09活性最优,其对人PBMC细胞中炎症因子TNF-α分泌的半抑制浓度曲线如图2所示,图2显示,化合物AG09对TNF-α分泌的半抑制浓度(EC50值)达3.51μM,为阳性对照化合物AG01的将近1/28,表明其对PBMC细胞分泌TNF-α的抑制活性为阳性对照化合物Arctiin(AG01)的约28倍,即,其抑制TNF-α分泌的活性明显优于Arctiin(AG01)。
此外,采用与上述相同的方法,还测试了本发明化合物AG09、AG26、AG27、AG28、AG29、AG31、AG32、AG33在5μM、1μM下对人PBMC细胞中炎症因子TNF-α分泌的抑制率,结果如以下表4所示。
表4化合物对PBMC细胞中炎症因子TNF-α分泌的抑制率
表4结果表明,本发明化合物AG09、AG26、AG27、AG28、AG29、AG31、AG32、AG33在5μM下也表现出对人PBMC细胞中炎症因子TNF-α分泌的极高的抑制率,特别是AG26、AG28、AG29、AG31、AG32、AG33;此外,部分本发明化合物(例如AG26、AG28、AG31、AG32、AG33)在1μM下也可以明显抑制人PBMC中TNF-α的分泌。
上述结果进一步证明,本发明化合物可以显著抑制人PBMC细胞中炎症因子TNF-α的分泌。
实施例21、本发明化合物对RAW264.7中TNF-α分泌的影响
肿瘤坏死因子(TNF-α)作为炎症、自身免疫病等疾病发展过程中重要的炎症介质,主要由活化的单核/巨噬细胞产生,可介导多种炎症反应的发生,加速恶化疾病进程。小鼠单核/巨噬细胞白血病细胞株RAW 264.7是常用的炎症细胞模型之一,在LPS诱导激活后,可释放TNF-α等多种炎症介质的释放。
将RAW 264.7细胞(1×10 5个/孔)接种于96孔板,孵育24h后,加入1μg/mL LPS诱导RAW 264.7细胞极化后,加入不同浓度的待测化合物(包括本发明的一系列化合物和阳性对照化合物Arctiin(AG01),于37℃,5% CO2培养箱中孵育18h。另设无刺激剂本底对照及刺激对照孔,总体积为200μL。300g/分钟,离心10min后收取上清,使用ELISA法检测培养上清中TNF-α的分泌水平。
实验结果如表5所示。
表5化合物对RAW 264.7细胞中炎症因子TNF-α分泌的抑制实验结果
表5结果表明,本发明化合物在100μM浓度下,可以明显抑制对RAW 264.7细胞中TNF-α的分泌,特别是化合物AG08、AG09,其活性优于Arctiin(AG01)将近2倍,提示:本发明化合物具有明显优于Arctiin(AG01)的抗炎效果。
实施例22、本发明化合物对银屑病样动物模型的治疗作用
1.实验材料:包含实施例5制得的AG09作为活性成分的软膏剂,所述软膏剂的制备方法如下:
(1)将液体石蜡15份,凡士林50份,单硬脂酸甘油酯50份,单硬脂酸100份,混合加热至70℃,得到油相A;
(2)将甘油100份,三乙醇胺2份,十二烷基硫酸钠2份,尼泊金乙酯1份溶于450份纯化水中,加热至70℃,加入40.5份AG09(即5%AG09),迅速搅拌溶解,得水相B;
(3)将油相A缓慢加入水相B中,不断搅拌,制成AG09软膏剂,静置,冷却。
2.造模药物:咪喹莫特软膏,由四川明欣利迪药业有限责任公司生产,国药准字H20030128,产品批号15060139。
3.实验动物:BALB/c小鼠,雌性,体重18-22g,由上海斯莱克实验动物有限公司提供。
4.银屑病样模型造模方法:小鼠剔除背部毛发后,对其背部皮肤每日涂抹62.5mg咪喹莫特软膏,涂抹时间约每日7:30,连续进行8天,此时,银屑病样皮损处于较为严重的水平,如图3的模型对照组所示。
5.实验方法:
实验共分四组:
(1)正常对照组(即,正常健康小鼠);
(2)模型对照组(即,未经任何治疗的银屑病样小鼠模型);
(3)AG09软膏剂5%治疗组(即,经5%AG09软膏剂治疗的银屑病样小鼠模型);
(4)AG09软膏剂2%治疗组(即,经2%AG09软膏剂治疗的银屑病样小鼠模型),每组10只动物;
其中:AG09软膏剂5%和2%治疗组的处理方式如下:对银屑病样小鼠模型的背部皮肤每日分别涂抹5% AG09软膏剂和2% AG09软膏剂62.5mg,涂抹时间约为每日18:30,连续进行8天。
6.评价方法:
通过以下方法,评价AG09软膏制剂对银屑病样动物模型的治疗作用:
1)实验终点,对各组小鼠拍照,记录皮肤出现红斑、增厚、鳞屑现象;其结果如图3所示;
2)实验终点,取各组小鼠皮肤组织,以进行H&E染色;具体地,收集皮肤样品,将其固定于10%福尔马林组织固定液中,包埋于石蜡,切成3μm切片并进行H&E皮肤组织染色,在Olympus IX73显微镜观察皮肤表皮增厚及炎症细胞浸润等;其结果如图4所示;
3)实验终点,取各组小鼠皮肤组织,以制作病理切片(病理切片由扫描仪扫描组织进行切片),并使用Image-Pro Plus软件(Silver Springs,MD,USA)对每个皮肤切片的表皮厚度进行定量;具体地,收集皮肤样品,将其固定于10%福尔马林组织固定液中,包埋于石蜡,切成3μm切片并进行H&E皮肤组织染色,使用Image-Pro Plus软件(Silver Springs,MD,USA)对每个皮肤切片的表皮厚度进行定量;其结果如图5所示。
图3-5结果表明:AG09软膏制剂(2%,5%)均能够有效缓解咪喹莫特诱导的小鼠银屑病样皮损,表现在:
I)如图3所示,模型对照组小鼠皮肤出现红斑、增厚、鳞屑现象,与模型对照组相比,外用AG09软膏制剂(2%,5%)对于咪喹莫特诱导银屑病小鼠皮肤的红斑、增厚及鳞屑具有明显的改善作用。
II)如图4所示,模型对照组小鼠皮肤角质形成细胞过度增殖、炎症细胞浸润明显,外用AG09软膏制剂(2%,5%)对表皮过度增殖和炎症细胞浸润有明显缓解。
III)如图5所示,与正常对照组相比,咪喹莫特诱导的银屑病样模型小鼠(即,模型对照组)表现出明显的表皮增厚,而用AG09软膏制剂(2%,5%)处理后,明显改善了这种表皮增厚,并且表现出剂量依赖效应。
上述结果均提示:本发明化合物AG09对于银屑病样小鼠模型具有明显的治疗效应,并且,随着活性化合物含量的增高,其治疗效力也明显增高。
最后应说明的是:以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (15)
1.如式(I)所示的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐:
所述式(I)中,R选自由以下组成的组:单糖、单糖衍生物、由单糖单元通过糖苷键连接的双糖、由三至五个单糖单元通过糖苷键连接的寡糖;其中,所述单糖不包含D-β-葡萄糖,但所述单糖衍生物包含D-β-葡萄糖衍生物,并且,其中,所述R通过α或β型O-糖苷键与二苄基丁内酯类化合物主体相连。
2.根据权利要求1所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐,其特征在于,所述单糖选自:呋喃糖和吡喃糖;
优选地,所述单糖为D型或L型。
3.根据权利要求1所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐,其特征在于,所述单糖衍生物选自由以下组成的组:氧化糖、卤代糖、不饱和糖、去氧糖、氨基去氧糖、脱水糖、硫酸化糖、磷酸化糖、歧链糖、糖基烷基化衍生物和糖基酯化衍生物;
优选地,所述氧化糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被氧化为醛或酸所得的单糖衍生物;
优选地,所述卤代糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被卤素取代所得的单糖衍生物,所述卤素任意地选自氟、氯、溴或碘;
优选地,所述不饱和糖选自单糖或单糖衍生物上任意相邻两个羟基变为不饱和双键所得的单糖衍生物;
优选地,所述去氧糖或氨基去氧糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被替换为甲基所得的单糖衍生物;
优选地,所述脱水糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被替换为氢原子所得的单糖衍生物;
优选地,所述硫酸化糖或磷酸化糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被硫酸基或磷酸基修饰所得的单糖衍生物;
优选地,所述歧链糖选自单糖或单糖衍生物上任意1,2,3,4或5个非端基碳原子上各自独立地有一个碳取代基所得的单糖衍生物,所述碳取代基可以置换为一个氢原子或一个羟基;
优选地,所述糖基烷基化衍生物选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被直链或支链的烷基修饰所得的单糖衍生物,所述烷基为C1-C10烷基或亚烷基、C1-C8卤代烷基、C3-C10环烷基、3-8元杂环烷基、C6-C10芳基、3-8元芳杂环基、3-8元杂环烷基C1-C8亚烷基、3-8元环烷基C1-C8亚烷基或C6-C10芳基C1-C8亚烷基;
优选地,所述糖基酯化衍生物选自由单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地与直链或支链的酰基组成酯键所得的单糖衍生物,所述酰基各自独立地为C1~C10烷基酰基、C1-C8卤代烷基酰基、C3-C10环烷基酰基、3-8元杂环烷基酰基、C6-C10芳基酰基、3-8元芳杂环基酰基、3-8元杂环烷基C1-C8亚烷基酰基、3-8元环烷基C1-C8亚烷基酰基或C6-C10芳基C1-C8亚烷基酰基,优选为乙酰基、丙酰基、异丁酰基、苯甲酰基。
4.根据权利要求3所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐,其特征在于,所述单糖衍生物选自由以下组成的组:卤代糖、不饱和糖、糖基烷基化衍生物和糖基酯化衍生物;
优选地,所述卤代糖选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被氟、氯、溴、碘原子取代;
优选地,所述不饱和糖选自单糖或单糖衍生物上任意相邻两个羟基变为不饱和双键所得的单糖衍生物;
优选地,所述糖基烷基化衍生物选自单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地被甲基、乙基、环丙基、苄基或对甲氧基苄基所取代,或任意两个羟基通过亚甲基、亚乙基、异亚丙基、苯亚甲基组成环状缩醛或缩酮所得的单糖衍生物;
优选地,所述糖基酯化衍生物选自由单糖或单糖衍生物上任意1,2,3,4或5个羟基各自独立地与乙酰基、丙酰基、异丁酰基或苯甲酰基组成酯键所得的单糖衍生物。
5.根据权利要求1所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐,其特征在于,所述R选自如下糖基或糖基衍生物:
柔红霉糖、阿洛糖、阿卓糖、古洛糖、半乳糖、氨基半乳糖、氨基葡萄糖、甘露糖、艾杜糖、塔洛糖、来苏糖、阿拉伯糖、核糖、木糖、岩藻糖、鼠李糖、异鼠李糖、橄榄霉糖、毛地黄毒糖、加拿大麻糖、奎诺糖、艾杜糖、6-脱氧艾杜糖、N-乙酰葡萄糖胺、N-乙酰半乳糖胺、果糖,或前述任意一项的衍生物,或D-β-葡萄糖衍生物。
6.根据权利要求1所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐,其为选自以下的化合物:
优选地,所述化合物选自以下:
/>
进一步优选地,所述化合物选自以下:
/>
/>
更进一步优选地,所述化合物为:
/>
7.一种如权利要求1-6任一项所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐的制备方法,其特征在于,所述制备方法包括以下步骤:
(1)牛蒡子苷元与乙酰基保护的糖,在氮气保护下,在催化剂作用下,经取代反应,形成乙酰基保护的牛蒡子糖苷化合物;
(2)在碳酸钾或甲醇钠存在下,使步骤(1)所得乙酰基保护的牛蒡子糖苷化合物脱去乙酰基保护,得到所述二苄基丁内酯糖苷类化合物。
8.根据权利要求7所述的制备方法,其特征在于,步骤(1)中,所述催化剂选自:三氟甲磺酸三甲基硅酯、三氟甲磺酸、三氟化硼乙醚、三氯化铁,优选为三氟化硼乙醚;
和/或,步骤(1)中,所述取代反应在溶剂中进行,所用溶剂选自:二氯甲烷、1,2-二氯乙烷、1,4-二氧六环,优选为二氯甲烷;
和/或,步骤(1)中,所述取代反应在-60℃~0℃,优选-50℃~0℃的温度下进行;
和/或,步骤(1)中,所述牛蒡子苷元与乙酰基保护的糖的摩尔比为0.05~3,优选为0.1~2;催化剂与牛蒡子苷元的摩尔比为0.008~1.2,优选为0.01~1。
9.根据权利要求7或8所述的制备方法,其特征在于,步骤(2)中,所用溶剂选自:二氯甲烷、丙酮、乙酸乙酯、甲醇、乙醇,优选为甲醇;
和/或,步骤(2)中,反应温度为20~30℃,优选为室温。
10.根据权利要求7-9任一项所述的制备方法,其特征在于,步骤(1)中,所述乙酰基保护的糖具有如下结构式:
所述制备方法按如下工艺路线:
步骤一
步骤二
其中,Ra选自:H、-CH2OAc、-CH3;
当Ra为H时,Rh也为H;当Ra为-CH2OAc时,Rh为-CH2OH;当Ra为-CH3时,Rh为-CH3。
11.一种药物组合物,其包括如权利要求1-6任一项所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐,以及药学上可接受的辅料。
12.根据权利要求11所述的药物组合物,其特征在于,所述二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐与药学上可接受的辅料的比重在0.001至100的范围内,优选在0.001至10范围内。
13.如权利要求1-6任一项所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐在制备磷酸二酯酶4抑制剂、优选磷酸二酯酶4D抑制剂中的用途。
14.如权利要求1-6任一项所述的二苄基丁内酯糖苷类化合物、其立体异构体、互变异构体或其药学上可接受的盐或者如权利要求11-12任一项所述的药物组合物在制备用于预防、治疗或辅助治疗与磷酸二酯酶4活性水平和/或表达水平异常相关的疾病的药物中的用途。
15.根据权利要求14所述的用途,其特征在于,所述磷酸二酯酶4为磷酸二酯酶4A、4B、4C或4D;
优选地,所述疾病为与磷酸二酯酶4活性水平和/或表达水平异常相关的免疫和/或炎症性疾病;
优选地,所述疾病为与磷酸二酯酶4A、4B、4C或4D活性水平和/或表达水平异常相关的免疫和/或炎症性疾病;
进一步优选地,所述疾病选自由以下组成的组:银屑病、银屑病关节炎、特应性皮炎、白塞氏病、脂溢性皮炎、过敏性皮炎、慢性阻塞性肺病、哮喘、过敏性鼻炎、强直性脊柱炎、系统性红斑狼疮、风湿性关节炎、类风湿性关节炎、炎症性肠病、恶性胶质瘤、肺纤维化、肌萎缩性侧索硬化症、多发性硬化症、阿尔兹海默症、亨廷顿舞蹈症、帕金森氏症、多动症、抑郁症和精神分裂症。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211078981 | 2022-09-05 | ||
CN2022110789812 | 2022-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117645641A true CN117645641A (zh) | 2024-03-05 |
Family
ID=90048345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311139551.1A Pending CN117645641A (zh) | 2022-09-05 | 2023-09-05 | 二苄基丁内酯糖苷类化合物、其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117645641A (zh) |
WO (1) | WO2024051666A1 (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010138081A (ja) * | 2008-12-09 | 2010-06-24 | Kansai Univ | インフルエンザウイルス免疫賦活剤、および抗インフルエンザウイルス剤 |
CN105732598B (zh) * | 2016-02-03 | 2018-07-27 | 辽宁中医药大学 | 牛蒡苷元醚类衍生物及其制备方法和用途 |
CN112823798A (zh) * | 2019-11-21 | 2021-05-21 | 中国科学院上海药物研究所 | 牛蒡子苷与牛蒡子苷元在制备治疗和/或预防皮肤炎症的药物中的应用 |
-
2023
- 2023-09-05 WO PCT/CN2023/116894 patent/WO2024051666A1/zh unknown
- 2023-09-05 CN CN202311139551.1A patent/CN117645641A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2024051666A1 (zh) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL151289B1 (en) | New ganglioside derivatives | |
Warashina et al. | Steroidal glycosides from the aerial part of Asclepias incarnata | |
Kouno et al. | Two new iridolactones and their glycosides from the roots of Patrinia scabra | |
Hatano et al. | Tannins of Coriaria japonica A. Gray. I.: Coriariins A and B, new dimeric and monomeric hydrolyzable tannins | |
Zi et al. | Glucoside derivatives of podophyllotoxin: Synthesis, physicochemical properties, and cytotoxicity | |
Pirrone et al. | Stereospecific Synthesis of Methyl 2-Amino-2, 4-dideoxy-6S-deuterio-α-D-xylo-hexopyranoside and Methyl 2-Amino-2, 4-dideoxy-6S-deuterio-4-propyl-α-D-glucopyranoside: Side Chain Conformation of the Novel Aminoglycoside Antibiotic Propylamycin | |
Xu et al. | Tannins and related compounds. CVII. Structure elucidation of three new monomeric and dimeric ellagitannins, flosin B and reginins C and D, isolated from Lagerstroemia flos-reginae Retz. | |
JPS63227599A (ja) | アンスラサイクリン化合物およびその用途 | |
Yoshimura et al. | Constituents of seeds of Ailanthus altissima Swingle. Isolation and structures of shinjuglycosides A, B, C, and D. | |
CN106083788A (zh) | 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法 | |
KR920000646B1 (ko) | 플루오로-치환 에피포도필로톡신 배당체 | |
CN106146581A (zh) | 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮与黄酮醇结合物及其制备方法和应用 | |
Yoshimura et al. | Flavonol glucuronides and C-glucosidic ellagitannins from Melaleuca squarrosa | |
CN117645641A (zh) | 二苄基丁内酯糖苷类化合物、其制备方法和应用 | |
Zhang et al. | Total synthesis, structural elucidation and anti-inflammatory activity evaluation of 2-deoxy-3, 6-anhydro hexofuranoside derivatives isolated from Sauropus rostratus | |
EP2716293B1 (en) | Anti-tumor agent | |
Ishida et al. | Studies on the antihemorrhagic substances in herbs classified as hemostatics in Chinese medicine. IX. On the antihemorrhagic principles in Typha lactifolia L. | |
Ishimatsu et al. | Tannins and Related Compounds. LXXIX. Isolation and Characterization of Novel Dimeric and Trimeric Hydrolyzable Tannins, Nuphrins C, D, E and F, from Nuphar japonicum DC. | |
CN108159040B (zh) | 一类木糖碳苷类药物的制备方法及用途 | |
WO2013097661A1 (zh) | 呋甾烷型皂苷衍生物及其用途 | |
Calis et al. | Periclymenosidic acid, a new biosidic ester iridoid glucoside from Lonicera coerulea | |
Li et al. | Synthesis and cardiac activity evaluation of the proposed structures of fuzinoside | |
Song et al. | Synthesis and biological evaluation of acylated oligorhamnoside derivatives structurally related to mezzettiaside-6 with cytotoxic activity | |
CN110003291B (zh) | 一种氟代糖基修饰的紫杉醇类化合物及其合成方法和应用 | |
JPH04316596A (ja) | エピポドフィロトキシングリコシド類 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |